A study of comorbidities, lifestyle risk factors and fatigue of patients with multiple Sclerosis in South Africa by Maartens, Desiree
A Study of Comorbidities, Lifestyle Risk Factors and Fatigue of Patients with Multiple 
Sclerosis in South Africa 
Desirèe Duane Maartens 
Thesis presented in fulfilment of the requirements for the degree of Master of Science in the Faculty 
of Medicine and Health Sciences at Stellenbosch University 
Dr Martin Heine - Supervisor 
Prof Wayne Derman – Co-supervisor 
December 2019 
ii 
DECLARATION 
By submitting this thesis electronically, I declare that the entirety of the work contained therein is my 
own, original work, that I am the sole author thereof (save to the extent explicitly otherwise stated), that 
reproduction and publication thereof by Stellenbosch University will not infringe any third party rights 
and that I have not previously in its entirety or in part submitted it for obtaining any qualification. 
Date: December 2019 
Copyright © 2019 Stellenbosch University All rights reserved 
Stellenbosch University https://scholar.sun.ac.za
iii 
Acknowledgements 
 Dr Martin Heine, your support, time, patience, encouragement and belief in me, made this
MSc possible. Thank you for challenging me to be more, do more and think more through this
MSc. I value your mentorship and guidance through this whole process. Thank you.
 Prof Wayne Derman, thank you for encouraging me to do my MSc and for your input and
guidance to making this MSc a reality.
 My husband, Ludwich and my two children, Kaylin and Joshua; thank you for giving me the
opportunity to do this MSc. You were my biggest fans and without the endless love, support
and cheering me on I am not sure I would have finished this. It has taken a community of
support to do this MSc and for the love and support from my friends and family I am ever
grateful.
 Thank you to the Multiple Sclerosis Society of South Africa and the participants of this study
for your time and invaluable information.
 My God and Saviour - Your grace has been sufficient for me and Your power has been made
perfect in my weakness – thank you.
Stellenbosch University https://scholar.sun.ac.za
iv 
Table of Contents 
Declaration ............................................................................................................................................. ii 
Acknowledgements ............................................................................................................................. iii 
Table of Contents ................................................................................................................................. iv 
List of Figures ....................................................................................................................................... v 
List of Tables ........................................................................................................................................ vi 
List of Abbreviations .......................................................................................................................... vii 
Abstract in English ............................................................................................................................ viii 
Abstract in Afrikaans ............................................................................................................................ x 
Chapter 1: Introduction ........................................................................................................................ 1 
Chapter 2: A Scoping Review of Multiple Sclerosis Research in sub-Saharan Africa between 
1967 and 2018 ...................................................................................................................... 5 
Chapter 3: A Cross-sectional Online Study on the characteristics, comorbidities and 
symptoms experienced by individuals with Multiple Sclerosis in South Africa ........ 17 
Chapter 4: Agreement between three self-report questionnaires to determine severe fatigue in 
Multiple Sclerosis – a cross-sectional online study ................................................... 37 
Chapter 5: Summary and conclusion ............................................................................................... 48 
References ............................................................................................................................................ 51 
Appendices ........................................................................................................................................... 62 
Stellenbosch University https://scholar.sun.ac.za
v 
 
List of Figures 
 
Figure 1.1: Prevalence of Multiple Sclerosis per country (2013) ............................................................ 2 
Figure 2.1: Flow Chart of the Data Synthesis ....................................................................................... 13 
Figure 3.1: ICF Model for the Characteristics of Multiple Sclerosis ...................................................... 20 
Stellenbosch University https://scholar.sun.ac.za
vi 
 
List of Tables 
 
Table 2.1: Overview of included studies per subcategory, and ordered alphabetically .......................... 9 
Table 3.1: Demographic Variables and Clinical Characteristics of Persons with Multiple Sclerosis in 
South Africa…………………………………………...………………………………………………………24 
Table 3.2: The Body Structure, Activity, Social Participation and Environmental Outcomes in Persons 
with Multiple Sclerosis in South Africa ……………………..…..………………………………..………… 25 
Table 3.3: The Fatigue, Social Participation, Sleep and Substance Abuse Outcomes of the Persons 
with Multiple Sclerosis in South Africa..…………………………………………………………….………..26 
Table 4.1: Demographic Variables and Clinical Characteristics of Persons with Multiple Sclerosis in 
South Africa …………………………………………………………………………………………….………43 
Table 4.2: The Fatigue Severity Scale, the Fatigue Scale for Motor and Physical Functions and the 
PROMIS Fatigue Short Form Questionnaires Median, Interquartile and Categorical Data for the 
Persons with Multiple Sclerosis in South Africa………………………………………………………….…44 
Table 4.3: Cohen’s Kappa for agreement and Spearman’s correlation for associations between the 
Fatigue Severity Scale, the Fatigue Scale for Motor and Physical Functions and the PROMIS Fatigue 
Short Form Questionnaires………………………………………………………………………………..….45 
Table 4.4: Optimal cut off values, sensitivity, and specificity, area under the curve, sensitivity 100% 
and specificity 100% for the Fatigue Severity Scale, the Fatigue Scale for Motor and Physical 
Functions and the PROMIS Fatigue Short Form Questionnaires........................................................45  
 
 
 
Stellenbosch University https://scholar.sun.ac.za
vii 
 
List of Abbreviations 
 
MS Multiple Sclerosis 
CNS Central Nervous System 
PwMS Persons with MS 
EBV Epstein - Barr virus 
SA South Africa 
PRISMA Preferred Reporting Items for Systematic  
  Reviews and Meta-Analysis Protocols 
DM Desirèe Maartens 
MH Martin Heine 
MSSA MS Society of South Africa 
STROBE Strengthening the Reporting of 
 Observational Studies in Epidemiology 
REDCap Research Electronic Data Capture 
BMI   Body Mass Index 
ICF  International Classification of Functioning 
PDDS  Patient Determined Disease Steps 
MSWS-12 MS Walking Scale 
PROMIS SF PROMIS Short Form 
IPAQ International Physical Activity Questionnaire 
METs Metabolic Equivalents 
PPP Purchasing Power Parity 
FSS Fatigue Severity Scale  
FSMC Fatigue Scale for Motor and Cognitive 
95% CI 95% Confidence Interval 
IQR Inter Quartile Range 
SES Socioeconomic Status 
ROC Receiving Operating Characteristics 
AUC  Area Under the Curve 
 
 
Stellenbosch University https://scholar.sun.ac.za
viii 
 
Abstract 
 
Background: Multiple Sclerosis (MS) affects approximately 2.3 million people globally. A geographical 
gradient in the prevalence of MS has been reported, with the lowest prevalence reported for sub-
Saharan Africa. The vast contextual differences between sub-Saharan Africa and developing countries 
may argue for a better understanding of MS in an African setting specifically.  
 
Aims and Objectives: The main aims of this thesis were to better understand MS in an African context 
by reviewing research conducted in Sub-Saharan Africa in the past, and build upon that knowledge by 
evaluating demographics and characteristics of pwMS in an African country (South Africa [SA]). The 
objectives were to;  
(i) scope the existing literature on MS, originating from sub-Saharan Africa (Chapter 2) 
(ii) evaluate the characteristics and key symptoms of pwMS in SA (Chapter 3), and  
(iii) investigate the agreement between the reported cut-off values for categorising severe fatigue, one 
of the key symptoms reported by patients with MS globally, by using three different questionnaires 
(Chapter 4). 
 
Methods:  
(i) A scoping review of the literature on MS from sub-Saharan Africa was undertaken.  
(ii) A cross-sectional online survey was developed and distributed to all pwMS in SA affiliated with 
the Multiple Sclerosis Society of SA (n=1048). Measures were included across all domains of 
the International Classification of Functioning model.  
(iii) The fatigue questionnaires (Fatigue Severity Scale (FSS), Fatigue Scale for Motor and 
Cognitive Functions (FSMC) and PROMIS Fatigue Short Form (SF)) included in the cross-
sectional study were subsequently used to determine their agreement in identifying patients 
with severe fatigue using previous reported cut-off values, and Receiver Operating Curves were 
developed to determine new robust cut-off values which acknowledge the unidimensional 
character of each questionnaire. 
 
Results: Thirty-three studies from sub-Saharan Africa were included for the scoping review. Four 
themes could be derived to group the included studies; aetiology (n=6), epidemiology (n=9), 
haematology (n=13) and other (n = 5). Majority of the studies (88%) were conducted in South Africa, 
and only few reports were from the last decade (9%). No comprehensive report on the characteristics 
and symptom experience of pwMS in sub-Saharan Africa was identified. Subsequently, 122 pwMS 
(11.6%) completed the anonymous survey (Age=4710yrs, Male (%) =14). PwMS were generally 
moderately disabled (30.2%) according to the Patient Determined Disease Steps. Comorbidity was 
frequent, with 39.3% of pwMS reporting three or more comorbidities. The most common comorbidities 
being: depression (36.1%), high blood pressure and high cholesterol (20.5%) respectively, migraines 
(15.6%) and anxiety disorders (13.9%).  The FSS, FSMC and PROMIS Fatigue SF categorised 73.9%, 
78.9% and 30% respectively as severely fatigued. Using Cohen’s Kappa, a significantly moderate 
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agreement was found between FSS and FSMC, (k = 0.563, p = 0.000), and not the PROMIS Fatigue 
SF. Cut-off values of 5.8 out of 7 for the FSS and 88.5 out of 100 for FSMC would provide 100% certainty 
a patient with these values (or higher) would have classified as having severe fatigue on both fatigue 
measures.  
 
Conclusion: Despite an increased reporting of MS in sub-Saharan Africa, there is very little recent 
research on the epidemiology and characteristics of patients with MS in this context. Intervention studies 
specifically developed for an African context were absent.  A triad of poor lifestyle behaviour, low levels 
of physical activity, and high burden of comorbidity were reported which are concerning in the light of 
the global burden of disease. Often hampered by the multi-dimensional character of fatigue, the 
developed robust cut-off values for fatigue could be used in future research where the presence of 
fatigue is important in for instance evaluating the benefits of interventions to tackle this key symptom. 
The results of this thesis can be used to set the stage for developing an African specific research agenda 
for MS. 
. 
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Abstrak 
 
Agtergrond: Veelvuldige Sklerose (MS) affekteer ongeveer 2.3 miljoen mense wêreldwyd. 'N 
Geografiese gradiënt in die voorkoms van MS is aangemeld, met die laagste voorkoms vir Afrika suid 
van die Sahara gerapporteer. Die groot kontekstuele verskille tussen Afrika suid van die Sahara en 
ontwikkelende lande kan spesifiek argumenteer vir 'n beter begrip van MS in 'n Afrika-omgewing. 
 
Doelwitte en doelstellings: Die hoofdoelwitte van hierdie proefskrif was om MS in 'n Afrika-konteks 
beter te verstaan deur navorsing in Afrika suid van die Sahara te hersien, en voort te bou op daardie 
kennis deur die demografie en eienskappe van pwMS in 'n Afrika-land (Suid-Afrika) te evalueer Afrika 
[SA]). Die doelwitte was om; 
(i) bestudeer die bestaande literatuur oor MS, afkomstig van Afrika suid van die Sahara (Hoofstuk 2) 
(ii) die eienskappe en sleutelsimptome van pwMS in SA (hoofstuk 3) te evalueer, en 
(iii) die ooreenkoms tussen die gerapporteerde afsnywaardes vir die kategorisering van ernstige 
moegheid, een van die sleutelsimptome wat deur pasiënte met MS wêreldwyd gerapporteer word, 
ondersoek deur drie verskillende vraelyste te gebruik (Hoofstuk 4). 
 
Metodes: 
(i) 'n Omvangbepalingsoorsig van die literatuur oor MS uit Afrika suid van die Sahara is onderneem. 
(ii) 'n Deursnee-opname is ontwikkel en versprei aan alle pwMS in SA wat geaffilieer is by die Multiple 
Sclerosis Society of SA (n = 1048). Maatreëls is ingesluit in alle domeine van die Internasionale 
Klassifikasie van Funksionele model. 
(iii) Die uitputtingsvraelyste (Fatigue Severity Scale (Fatigue Severity Scale (FSS)), Vermoeidheidskaal 
vir Motoriese en Kognitiewe Funksies (FSMC) en PROMIS Fatigue Short Form (SF)) wat in die 
dwarssnitstudie ingesluit is, is later gebruik om hul ooreenkoms te identifiseer om pasiënte te 
identifiseer met erge moegheid deur gebruik te maak van vorige gerapporteerde afsnywaardes, en 
Ontvanger Bedryfskurwes is ontwikkel om nuwe robuuste afsnywaardes te bepaal wat die 
unidimensionele karakter van elke vraelys erken. 
Resultate: Drie-en-dertig studies uit Afrika suid van die Sahara is ingesluit vir die omvangsbepaling. 
Vier temas kan afgelei word om die ingesluit studies te groepeer; etiologie (n = 6), epidemiologie (n = 
9), hematologie (n = 13) en ander (n = 5). Meerderheid van die studies (88%) is in Suid-Afrika uitgevoer, 
en slegs enkele verslae was van die afgelope dekade (...%). Geen omvattende verslag oor die 
eienskappe en simptome-ervaring van pwMS in Afrika suid van die Sahara is geïdentifiseer nie. 
Vervolgens het 122 pwMS (11.6%) die anonieme opname voltooi (Ouderdom = 47 ± 10 jaar, Manlik 
(%) = 14). PwMS was oor die algemeen matig gedeaktiveer (30.2%) volgens die pasiëntbepaalde 
siektetoestande. Komorbiditeit was gereeld, met 39.3% van PwMS wat drie of meer comorbiditeite 
rapporteer. Die FSS, FSMC en PROMIS Moegheid SF het onderskeidelik 73.9%, 78.9% en 30% as 
ernstig vermoeid geraak. Met behulp van Cohen se Kappa is 'n beduidende matige ooreenkoms tussen 
FSS en FSMC gevind, (k = 0.563, p = 0.000), en nie die PROMIS-moegheid SF nie. Afsnywaardes van 
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5.8 uit 7 vir die FSS en 88.5 uit 100 vir FSMC sal 100% sekerheid bied. 'N Pasiënt met hierdie waardes 
(of hoër) sou geklassifiseer het as 'n ernstige moegheid op beide moegheidsmaatreëls. 
 
Gevolgtrekking: Ondanks die toenemende rapportering van MS in Afrika suid van die Sahara, is daar 
baie min onlangse navorsing oor die epidemiologie en eienskappe van pasiënte met MS in hierdie 
konteks. Intervensiestudies wat spesifiek vir 'n Afrika-konteks ontwikkel is, was afwesig. 'N triade van 
swak lewenstyl gedrag, lae vlakke van fisiese aktiwiteit, en 'n hoë las van comorbiditeit is aangemeld 
wat aangaan in die lig van die wêreldwye las van siekte. Dikwels deur die multidimensionele karakter 
van moegheid belemmer, kan die ontwikkelde sterk afsnywaardes vir moegheid gebruik word in 
toekomstige navorsing waar die aanwesigheid van moegheid belangrik is, byvoorbeeld om die voordele 
van intervensies te evalueer om hierdie belangrike simptoom aan te pak. Die uitslae van hierdie 
proefskrif kan gebruik word om die verhoog te stel vir die ontwikkeling van 'n Afrika-spesifieke 
navorsingsagenda vir MS. 
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CHAPTER 1 
Introduction and scope of thesis 
 
Multiple Sclerosis (MS) is a chronic neurologic disease which has an autoimmune-mediated 
inflammatory and neurodegenerative impact on the central nervous system (CNS). It predominantly 
affects individuals in their early adult life, and has a significant impact functionally, financially, and on 
quality of life.(1) The pathogenesis of MS is not fully understood but it is thought that when lymphocytic 
infiltration through the blood-brain-barrier into the CNS occurs, this causes inflammation of the myelin, 
which is the protective sheath of nerves.(2) The inflammation also affects the axons themselves, as 
well as the oligodendrocytes and microglia which are cells that are important in supporting and 
protecting the myelin.(2) For the most part, the initial damage to the affected axons, can be repaired 
through remyelination. Reoccurring inflammation of the myelin will lead to progressive and long term 
damage of the CNS due to remyelination not being a sustainable solution to repairing the inflamed 
axons.(3) This results in the overall volume and integrity of the brain being affected. This 
neurodegeneration of the CNS is thought to be the primary cause of the disability in persons with MS 
(pwMS). The initial incident of inflammation of the myelin may be due to the interaction between the 
role of both genetic and environmental factors.(2) The genetic contribution to developing MS, is likely 
due to the familial recurrence rate of about 20%.(2) The risk reduction changes from 3% in first-degree 
relatives (siblings, 5%; parents, 2%; and children, 2%), to 1% in second-degree and third-degree 
relatives.(1,2) There are specific genes associated with the development of MS and there is over 200 
sequence allelic variants in multiple genes that increase a person’s susceptibility to MS.(4) 
 
The environmental factors that are known to contribute to the development of MS are a deficiency in 
Vitamin D, obesity in early life and cigarette smoking.(5–7) Checking and correcting Vitamin D 
concentrations may be an important prevention for developing MS.(1) Cigarette smoking risk associated 
with MS increases with duration and intensity and the risk is higher for men than woman.(1) There is a 
twofold increase in risk for men and woman who are obese early in life and may also be associated 
with lower vitamin D concentrations in obese individuals.(1) The involvement of the Epstein-Barr virus 
(EBV) as a contributing factor to the development of MS has been extensively studied. Studies have 
shown that people are at a higher risk of developing MS that have high concentrations of anti-EBV 
antibodies,(8) the association between MS development and EBV infection in children has also been 
found,(9) and there is a hypothesis that the EBV infects B cells which then produce autoantibodies and 
produce antigens to self-reactive T-cells.(10,11) These studies show that there are strong arguments 
pointing towards EBV’s involvement in MS but as to how to deter its involvement (such as a vaccine 
development) is still up for discussion.(12) 
 
Signs and symptoms of MS vary widely and depend on the amount of nerve damage and which areas 
of the CNS are affected. Some people with severe MS may lose their ability to walk independently or 
even are unable to walk at all, while others may experience long periods of remission without any new 
symptoms. Overtime, there is an accumulation of disability including comorbidities such as 
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hypercholesterolemia and hypertension, as well as fatigue, depression and cognitive dysfunction which 
affect the patient’s quality of life and societal participation.(2,13–16) 
 
Figure 1.1: Prevalence of Multiple Sclerosis per country (2013)(17) 
 
©The MSIF Atlas of MS 2013 
 
There are an estimated 2.3 million people living with MS globally.(14) Figure 1.1 shows the prevalence 
of MS per country globally. MS is common in regions populated by northern Europeans,(2) but this 
effect can be redistributed according to where people live early on in life.(1) Migration from high-risk to 
low-risk regions as a child is associated with a reduced risk and migrating from a low to a high 
prevalence part of the world increases the risk of developing MS.(2,18)  
 
The information available of pwMS in sub-Saharan Africa is limited as historically, it has been thought 
that MS is not a disease of a predominant black population. Furthermore, a black patient that presents 
with an apparent MS phenotype is investigated for possible alternative explanations and often left with 
an unclear diagnosis or idiopathic/nonspecific CNS demyelination.(19) In a country such as South Africa 
(SA), the prevalence of MS is low (4 to 5 per 100 000) relative to the worldwide prevalence of MS which 
is 33 per 100 000.(13,14) It is perhaps due to the low prevalence of MS in SA, that there is a very little 
research on MS beyond the level of basic epidemiology.  
 
While the profile of pwMS in the northern hemisphere is well documented, and factors contributing to 
the health state such as fatigue, depression, sleep issues, cognitive and motor function problems are 
well documented, it can be hypothesized that their relative contribution might to some extend be context 
specific. For example; this could be on a micro level (e.g. rural versus peri-urban setting), macro level 
(e.g. latitude, exposure to vitamin D), as well as country-specific (e.g. medical insurance which gives 
one access to private medical care vs use of the public health care system). Therefore, the main aims 
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of this thesis were to better understand MS in an African context by reviewing research conducted in 
Sub-Saharan Africa in the past, and build upon that knowledge by evaluating demographics and 
characteristics of pwMS in an African country (South Africa). 
 
The research question for the first part of this MSc thesis was: what does the existing literature on MS 
in sub-Saharan African reveal about the epidemiology and symptoms of MS? The objective of this 
question was to gain a better understanding of the prevalence of MS in sub-Saharan Africa through a 
scoping review which will give knowledge of the current research of MS in sub-Saharan Africa and 
reveal gaps which can lead to future studies. The scoping review of MS in Sub-Saharan Africa is 
presented in Chapter 2.  
 
The second research question was: how does MS present in an African country and do the symptoms 
and experiences of pwMS differ from pwMS in the northern hemisphere? The second objective was to 
gain insight into the specific characteristics and symptoms of persons living with MS in South Africa 
(SA). To that extent, a national cross-sectional online survey has been performed to describe the 
characteristics and symptoms experienced by pwMS in SA and identify the key gaps in our knowledge 
and give direction for future studies. The results from the cross-sectional study are presented in Chapter 
3. 
 
The third research question was: how can the fatigue questionnaires used in the online survey in 
Chapter 3, identify and explain fatigue in pwMS and be more relevant to pwMS who experience severe 
fatigue? In studying MS, the symptoms that a pwMS experiences becomes increasingly important to 
understand. The symptoms can be debilitating such as pain and fatigue and can affect every aspect of 
life. The symptoms can interfere in one’s ability to work, interact socially and even sleep and eat. Fatigue 
is such a symptom experienced by majority of pwMS and is often hard to fully define as it’s a subjective 
experience and therefore difficult to do research interventions. There is much research on fatigue in 
pwMS but there are studies showing that the evidence to support fatigue interventions is not 
methodologically robust to be able to use that information for the evidence-based management of 
fatigue in pwMS.  
 
There are many questionnaires used in research and clinical practice to assess fatigue and its severity. 
It has been argued that often these questionnaires only assess a single aspect or dimension of fatigue, 
(20) and hence the use of more than one questionnaire in clinical research has been suggested to cover 
a broader aspect of the fatigue construct. Despite each questionnaire having specific, validated, cut-
offs to identify “severe” fatigue, we’re uncertain that if different questionnaires are used to assess severe 
fatigue, one would be 100% certain that all pwMS categorised as severely fatigued on one questionnaire 
would be also categorised as severely fatigued on another? Therefore, this leads to the third objective 
of this thesis, which was to describe new cut off points for three frequently used fatigue self-reporting 
questionnaires. These new cut-offs will then assist researchers in including all pwMS that suffer with 
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severe fatigue across multiple questionnaires in clinical research. The results for these new cut-offs are 
presented in Chapter 4.  
 
Then finally, in Chapter 5 the joint findings of chapter 2 – 4 are discussed and recommendations for 
future research provided. 
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CHAPTER 2 
A Scoping Review of Multiple Sclerosis Research in sub-Saharan Africa between 1967 and 
2018 
Abstract 
Background: Multiple Sclerosis (MS) affects approximately 2.3 million people globally, with the 
prevalence of MS being highest in Europe and North America, and lowest in sub-Saharan Africa. 
However, despite the low prevalence, an increasing incidence of MS in sub-Saharan Africa in observed. 
The objective of this scoping review is to provide a synthesis of original studies in patients with MS 
(pwMS), originating from sub-Saharan Africa. This review facilitates a better understanding of the 
academic and health landscape involving patients with MS in Sub-Saharan Africa, and would assist 
identification of research gaps which can help inform future studies. 
 
Methods: A scoping review was conducted on the 7th of September 2018 in the online databases 
PubMed, SCOPUS, Web of Science, and EBSCO Host. A descriptive analysis along with a qualitative 
synthesis of the included studies was conducted. 
 
Results: Thirty-three studies from sub-Saharan Africa were included.  The majority of identified studies 
(n = 29 [88%]) was conducted in South Africa. The studies were predominantly of cross-sectional design 
(n = 28 [85%]); no randomized clinical trials were identified. Furthermore, most studies (n = 23; 70%) 
focused on Caucasian pwMS. Three studies (9%) originated from the last decade. The objectives of 
the included studies could be grouped under four themes: aetiology (n = 6), epidemiology (n = 9), 
haematology (n = 13) and other (n = 5). 
 
Conclusion: Most studies conducted in sub-Saharan Africa have focussed on increasing 
understanding of the aetiology and working mechanism of MS, predominantly in the context of the high 
incidence rates of MS in developed countries. Only few studies have been conducted with the primary 
aim of understanding MS patient care across the continuum, and management of MS in an African 
context. A better understanding of the working mechanisms behind the apparent increase of MS 
prevalence in sub-Saharan Africa, can inform academic and health systems, to facilitate evidence-
based and contextualized management of MS. 
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2.1 Introduction 
There are an estimated 2.3 million people living with Multiple Sclerosis (MS) globally.(14) The majority 
of persons with MS (pwMS) live in Europe and North America, (108 and 140 per 100,000 respectively) 
and the lowest incidence is in sub-Saharan Africa and East Asia, at 2.1 and 2.2 per 100,000 
respectively.(17) The prevalence of MS in sub-Saharan Africa has not been fully investigated as 
historically, it has been thought that MS is not a disease of the black population.(21) A black patient 
that presented with an apparent MS phenotype has historically been investigated for possible alternative 
pathological explanations and often left with an unclear diagnosis or idiopathic/nonspecific central 
nervous system (CNS) demyelination.(21)  
The earliest cases of MS recorded in sub- Saharan Africa were reported by Dean in a review in 1949, 
yet these were in Caucasian South Africans.(22) Subsequently, the first cases of MS in black Africans 
were recorded in 1970. Foster and Harries confirmed two cases in Kenya,(23) and in the timespan of a 
decade, 10 cases were confirmed in Uganda in between 1970 and 1980.(24) Since the 1980’s only a 
handful of studies have reported cases of MS in black Africans,(13,25–30) which may indicate the low 
prevalence of pwMS in sub-Saharan Africa. However, more recent studies show increasingly that MS 
does occur, albeit rarely, in black Africans.(13,17,30) The Atlas of MS survey conducted in 2008, listed 
3341 known cases of MS in sub-Saharan Africa which subsequently increased to 3992 cases by 
2013.(17) The reasons for this increase in the prevalence of MS in sub-Saharan Africa may be 
multifactorial, and may include a growing awareness of MS, increased access to medical care, 
increased local medical expertise, increased number of neurologists, accessibility and availability of 
new diagnostic procedures, and resources.(31) Despite the apparent increasing incidence, little 
research has been conducted that focuses on the management of patients with MS in an African 
context. Hence, the objective of this scoping review is to provide an overview of original studies in 
patients with MS, originating from sub-Saharan Africa; with the aim to facilitate a better understanding 
of the academic landscape involving patients with MS in Sub-Saharan Africa, and would help to identify 
any research gaps which may help inform future studies. 
2.2 Methods 
This protocol was drafted using the PRISMA Extension for Scoping Reviews (PRISMA-ScR) [Please 
see Appendix F for the checklist].(32). A scoping review is used to assess broad topics in a specific 
area of research and the area of research has many different study designs. A scoping review is helpful 
when the research question is not very specific nor is assessing the quality of the included studies a 
priority.(33) Therefore, the scoping review was chosen due to the objective of this chapter which was 
to give an overview of studies of pwMS in sub-Saharan Africa so that research gaps can be identified 
to inform future studies. The following bibliographic databases were searched on the 7th of September 
2018: PubMed, SCOPUS, Web of Science and EBSCO Host. The search strategies were discussed 
with an experienced librarian from the University of Stellenbosch, and further refined through discussion 
between the two reviewers. The final search strategy for PubMed can be found in Appendix A. 
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2.2.1 In/Exclusion criteria 
Studies on multiple sclerosis that were: peer-reviewed, original research in humans, written in English, 
and conducted in sub-Saharan Africa were included. Non-original research (e.g. conference 
proceedings, letters, reviews, and guidelines) as well as case studies were excluded. Case studies 
were excluded due to them predominantly referring to uncertainty in the diagnostic process of MS in 
specific subsamples. The case studies provide little information on the study design or methods and 
some information on the practice of diagnosing MS at the time of the case studies. A single reviewer 
(DM) reviewed, removed duplicates and screened titles. Subsequently, two reviewers, (DM and MH), 
independently screened the titles and abstracts (if available) to determine if the articles fitted the 
inclusion framework for the review. Any disagreements were discussed until consensus was reached. 
Finally, full-text articles were sourced, and data was charted by a single reviewer (DM), and data 
extraction was verified by a second reviewer (MH). 
 
2.2.2 Data extraction 
The data-charting form was jointly developed by the research team, and the form was continuously 
updated through an iterative process. Any disagreements were resolved through discussion between 
the two reviewers. We extracted data on article characteristics (e.g., country of origin, year of 
publication), type of study (e.g., cross-sectional, prospective cohort or retrospective cohort), divided the 
articles into themes (e.g., epidemiology, aetiology, haematology etc.), study population, aim of the 
study, methodology and important results. Methodological quality of RCTs is determined using the 
Cochrane Risk of Bias tool if applicable.(34) No random controlled trials (RCTs) were identified in this 
review and therefore no critical appraisal of  RCTs were required.  
 
2.3 Results 
After duplicates were removed, a total of 117 citations were identified from searches of electronic 
databases. Based on the title and the abstract, 50 were excluded, with 67 full text articles to be retrieved 
and assessed for eligibility. After the 67 full text articles were retrieved 33 studies were considered 
eligible for this review (see Figure 2.1). The included studies are presented in Table 2.1, and could be 
grouped according to the following themes: aetiology, epidemiology, haematology, and other. Under 
each theme, summaries of the country of origin, population, study design, aim, methodology and broad 
findings of each study were analyzed.  
2.3.1 Study characteristics 
The majority of the studies were conducted in South Africa (n=29; 88%), followed by Kenya (n=2; 6%), 
Uganda (n=1; 3%) and Zimbabwe (n=1; 3%). There were six studies related to the aetiology of MS, 
nine studies reported on the epidemiology of MS, thirteen studies reported on haematology in MS, and 
five studies could not be classified under the previous three groupings (i.e. other). The vast majority of 
the studies used a cross-sectional design (n=28), retrospective cohort analyses (n=4) and prospective 
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cohort analyses (n=1). The studies that were included in this review were published from 1967 to 2018 
with 21 research papers published in the last decade. There was only one intervention study.(35) The 
majority of the studies focused on Caucasian pwMS (n=23; 70%), followed by pwMS from different 
ethnic backgrounds (n=7; 21%), studies on only black pwMS specifically (n=2; 6%) and mixed ancestry 
(n=1; 3%).
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Table 1.1 Overview of included studies per subcategory, and ordered alphabetically. 
Citation, 
author, date 
CO ST Demographics Aims of the study Methodology Key findings 
Aetiology 
(36) Davis 
2014 
ZA CS 114 unrelated Caucasian 
ZA pwMS (98 females). 
195 unrelated Caucasian 
controls without 
neurological diseases (128 
females)  
To investigate the mechanism 
underlying homocysteine 
accumulation in MS patients as 
there is a link between 
homocysteine and obesity as 
risk factors for MS 
A total of 114 patients and 195 
population-matched controls were 
analysed for the FTO rs9939609 
polymorphism through DNA analysis 
Homocysteine concentrations were 
measured in a subgroup of 60 patients 
and 87 controls screened for multiple 
vascular risk factors through biochemical 
analysis. 
A questionnaire to determine diet scores 
and lifestyle factors 
The risk-associated FTO rs9939609 A-allele was associated 
with raised homocysteine concentrations in pwMS, but not in 
controls. 
Homocysteine concentrations correlated positively with BMI 
and total cholesterol concentrations. 
Identifying the FTO rs9939609 means adequate fruit, 
vegetables and folate and a diet low in saturated fats is 
important. 
 
(37) de 
Villiers 2006 
ZA CS  49 unrelated Caucasian 
ZA pwMS of European 
decent and 33 of their 
close relatives all with the 
SLC11A1 gene and 39 
controls same age and 
population group. 
To investigate the role of viral 
infection in ZA in pwMS in 
relation to specific SLC11A1 
genotypes 
Serum and peripheral blood mononuclear 
cells were screened for the presence of 
MS-associated retrovirus (MSRV) and two 
herpes virus (HHV-6 and EBV) 
sequences 
MSRV had a significantly higher frequency 
HHV-6 and EBV less significant 
Viral sequences detected in the unaffected close relatives of 
pwMS 
MSRV primary causative for MS in ZA population 
(38) Dean 
1971 
ZA CS  123 Caucasian pwMS not 
born in ZA 
To identify the age at which 
immigrants entered ZA and 
therefore determine the age of 
risk for developing MS 
Survey of all British and Northern 
Europeans who entered ZA between 
1900 to 1968 
91 (53 British and 38 other Europeans) developed MS after 
immigration.12/91 were under 15 on arrival. Suggests early 
immigration to a low risk area reduces the risk of MS 
Mean onset is 37 years  
(39) Fewster 
1979 
ZA CS  74 Caucasian (46 born in 
ZA); 55 females and 12 
Mixed ancestry; 10 
females of ZA pwMS. 
73 Caucasian and 11 
Mixed ancestry sex 
matched controls 
To determine the relationship 
of higher measles antibody 
titres and certain HLA antigens 
in pwMS in a low incidence 
setting (ZA) 
Diagnosis of MS used Schumacher 
criteria 
Measles antibody titres were determined 
by the hemaglutination inhibition test and 
HLA antigens were determined 
serologically by a microlymphocytotoxicity 
test 
52.1% Caucasian pwMS had significantly higher titres 
57.1% Caucasian born pwMS had significantly higher titres 
No difference in the Mixed ancestry 
No significant differences in the tissue typing 
(40) Fewster 
1984 
ZA CS  24 unrelated Mixed 
ancestry ZA pwMS. 190 
healthy, unrelated mixed 
ancestry controls with 
HLA-A, HLA-B and HLA-
DR antigens 
To determine HLA antigens in 
mixed ancestry pwMS in ZA 
Diagnosis of MS used Poser criteria 
Lymphocyte typing used to test for the 
antigens 
No significant difference between the pwMS and the controls 
for HLA-A and HLA-B antigens. 
A trend towards an association between HLA-DR2 
Overall the HLA antigens significantly lower than the 
Caucasian pwMS (Fewster 1979) (39) 
(41) Lowe 
1980 
ZW CS 40 Caucasian ZW pwMS 
35 immigrants, 5 born in 
Africa 
705 Caucasian ZA 
controls 
To determine HLA antigen in 
Caucasian ZW pwMS  
Lymphocyte typing of 29 antigens 6/29 significant differences to the controls;HLA-A9 had the 
highest significant frequency HLA-A29, B7, B17 were also 
increased; HLA-A1 was higher in the controls; HLA-A28 was 
completely absent in pwMS 
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Citation, 
author, date 
CO ST Demographics Aims of the study Methodology Key findings 
Epidemiology 
(25) Adam 
1989 
KE PC 6 Black 
Kenyans (4 
females) 
Identify MS in the 
Black Kenyan 
population 
Cases diagnosed by Poser criteria 
between Nov 1983-Oct 1988 at the 
Kenyatta National Hospital 
 
Age of onset 12-30 years. 
No difference in the clinical presentation of MS to northern latitudes.  
Theory that MS is a childhood viral infection that is brought into the areas of low risk by 
the settlers from Europe.  
(28) Bhigjee 
2007 
ZA CS  167 medical 
charts of ZA 
(123 females) 
 
To determine the 
period prevalence of 
MS in KZN in the 
different racial groups, 
using the revised 
McDonald’s criteria. 
 
 All patients were contacted telephonically 
over a period of one month (July 2005) to 
determine whether they were still alive and 
still resident in KZN.  
Clinical, laboratory and treatment data 
were also extracted from the charts 
 
MS in KZN is more frequent than previously believed. 
Occurs in all racial groups: Caucasians (105), Indians (48), Blacks (12) and mixed 
ancestry (2).  
Optic neuritis found in 26% of the pwMS. Age at onset ranged 15-75years.  
The clinical features were similar to the Western world 
 
(42) Bird 1969 ZA RC 42 Caucasian 
ZA pwMS (25 
females) 
To show the incidence 
of MS in ZA 
PwMS records from a private consulting 
neurological practice in Johannesburg 
during the years 1959-July 1968. 
Diagnosis was a clinical using McAlpine 
criteria. 
38 were born in ZA. The average age was 39.9 years.  
No Black ZA diagnosed.  
Theory of an infective basis is the cause of the increased incidence. 
 
(43) Bird 1975 ZA RC 53Caucasian 
ZA pwMS (33 
females) 
To compare 
environmental factors 
in ZA and Japan and 
the changes that took 
place for the increased 
incidence of MS 
 
PwMS records from a private consulting 
neurological practice in Johannesburg 
during the years 1959-70 
49 were born in ZA.  
Incidence rose from 5.46/1000 in 1962 to 7.69/1000 in 1970.  
Increased incidence of MS among the Caucasian ZA. 
No Black South Africans reported with MS. Theory: an infective element-probably from 
a high- risk area is the cause 
 
(44) Dean 
1967 
ZA CS  281 
Caucasian ZA 
pwMS (158 
born in ZA and 
123 
immigrants) 
To show the 
incidence, prevalence 
and mortality of 
Caucasian pwMS in 
ZA 
Patient records including death certificates 
from all over ZA from 1958 to 1966 were 
sought through doctors, hospitals, and the 
MS society.  
 
101of the pwMS born in ZA were English speaking.  
40/101 had both parents born in Europe. 22/101 had one parent born in Europe. 
Incidence was 0.6/100,000 for 1945-54.  
The prevalence rate for Caucasian ZA of 9.1/100,000 (males 5.4, females 12.8). 
English speaking 10.9/100,000. Mean age of onset was 31 years.  
The mean from onset to diagnosis was 8 years.  
(12) Kanyerezi 
1980 
UG RC 10 UG 
Africans (6 
females) 
To report cases of 
pwMS  
Medical records from July 1969 – July 
1979 
Mean age 29 years 5 cases found in 1978-1979 
Disease presents similarly to Europe 
(27) Kioy 2001 KE RC 9 KE; 7 
females 
(2 Indo-Asian 
ethnicity) 
To report the 
occurrence of MS 
among Black Kenyans 
who have never been 
out of the country  
Patients referred to a private neurology 
and clinical electrophysiology clinic 
Mean age of onset: 24years 
Mean duration since onset: 4 years 
MS had similar presentation to western countries 
Mean EDSS:4.5 
 
(13) Modi 
2008 
ZA CS 430 ZA pwMS  To determine 
qualitative data of 
pwMS in ZA 
Country wide survey on the Multiple 
Sclerosis Society of ZA website 
73% female; 3:1 female ratio; 71% 30-59 years old; 46% RRMS 
89% Caucasian, 3% Mixed ancestry, 3% Indian, <1% Black 
91% diagnosed by a neurologist 
(45)Rosman 
1985 
ZA CS Caucasian ZA 
Afrikaans 
pwMS 
Pilot study of 
incidence of MS in 
Caucasian Afrikaans  
 
Study ran from 1 March 1984 to 28 
February 1985. 
Poser et al. criteria used to diagnose 
 
5 new cases diagnosed in 12 months. Annual incidence of 1.6/100 000.Significant rise 
in the incidence of MS in Caucasian Afrikaans-speaking South Africans 
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Citation, 
author, 
date 
CO ST Demographics Aims of the study Methodology Key findings 
Haematology 
(16,18, 
19,23–25) 
Hon * 
2009; 
2009c; 
2009d; 
2012c; 
2013; 
2014 
ZA CS 31 Caucasian ZA females 
pwMS and 30 Caucasian 
female controls 
To determine in pwMS: the erythrocyte membrane 
fatty acid concentrations and correlate with EDSS; 
the fatty acid composition within the different 
phospholipid cell membrane; the differences in RBC 
membrane fluidity and permeability, as measured by 
the relationship between membrane phospholipids, 
fatty acids and cholesterol; the presence of EBV; the 
decrease in cell membranes fatty acid C20:4n-6 was 
associated with abnormalities in the prostaglandin 
E2 pathway and whether the prevalence of human 
herpesvirus-6 and varicella zoster virus could be 
associated with different stages of activity of the 
disease as well as the inflammatory status of the 
patients all in comparison to healthy controls 
 
FA composition measured by 
GC 
Phospholipids measured using a 
colorimetric assay, Cholesterol 
by an enzymatic assay 
CRP by a Beckman 
nephelometer 
PCR and ELIZA assays for viral 
DNA and antibody screening for 
EBV 
Enzyme linked immunosorbent 
assays  
Polymerase chain reaction 
assays for human herpesvirus-6 
and varicella zoster virus 
C20:4n-6 concentrations lower pwMS and correlated inversely 
with the EDSS 
Specific long chain SATS may increase risk of developing MS 
Increased inflammation status in pwMS influences membrane 
fluidity due to membrane lipid composition 
Higher prevalence rates for EBV in pwMS, IgM association 
with relapse episodes showing viral re-activation a contributing 
factor to relapses in pwMS 
Increased prostaglandin E2 concentration in plasma 
decreases C20:4n-6 which could contribute to CNS damage in 
pwMS 
Human herpesvirus-6 or varicella zoster virus have no 
causative role in the aetiology of MS 
 
(52–55)  
Hon # 
2009b; 
2011; 
2012a; 
2012b 
ZA CS 26 Caucasian ZA females 
pwMS and 30 Caucasian 
female controls 
To investigate in pwMS: the fatty acid composition 
within the different membrane phospholipid fractions 
in peripheral blood mononuclear cells; whether the 
blood cell membrane monounsaturated fatty acids 
were associated with inflammation and disease 
outcome; the relationship between peripheral blood 
mononuclear cell membrane fluidity, permeability 
status, and disease outcome measured by EDSS; 
NEFA concentrations in blood cell membranes and 
to correlate possible changes with disease outcome 
all in comparison to healthy controls  
 
Fatty acid composition and RBC 
membranes measured by GC; 
Phospholipids, FA and 
cholesterol composition in 
peripheral blood mononuclear 
cells determined by colorimetric 
assay, GC and enzymatic 
assays; 
 
The elongation product of 20: 4n-6, 22: 4n-6, was significantly 
decreased in membrane phosphatidylethanolamine and 
phosphatidylserine and correlated inversely with severity of 
EDSS and CRP. The inflammatory aspect of MS may be 
connected to n-9 and n-7 FA and polyunsaturated FA 
Correlation studies showed lipid metabolic abnormalities 
between membrane fluidity which may show immune cell 
membranes involvement in disease progression. 
Decrease in NEFA results in metabolic abnormalities and in 
immune cell membranes would influence the cell function and 
have a positive correlation between FAs and MS progression. 
(56) Kotze 
2001 
ZA CS 104 Caucasian ZA Afrikaans 
pwMS and 522 Caucasian 
controls 
To investigate the likelihood that iron dysregulation 
in association with infectious and/or autoimmune 
disease susceptibility may underlie the MS 
phenotype in a subgroup of patients 
The functional Z-DNA forming 
repeat polymorphism of the 
NRAMP1 gene was analysed 
Allele 5 of the NRAMP 1 is maintained in this population group 
but if it related to dysregulation of iron or modified susceptibility 
to viral infection and/or autoimmunity is unknown 
(57) Kotze 
2006 
ZA CS 118 Caucasian ZA pwMS 
and 102 healthy controls 
To determine the impact of iron overload on clinical 
outcome of MS through HH mutations, H63D and 
C282Y  
DNA screening  No significant difference between pwMS and controls for the 
mutations. 17 pwMS 17pwms heterozygous for C2827, 3 had 
below normal and none had above normal transferrin 
saturation concentrations 
(35) van 
Rensburg 
2006 
ZA CS 41 ZA pwMS; 32 
Caucasians, 7 mixed 
ancestry, 2 Black (37 
females) and 30 healthy 
matched controls 
To determine iron status, folate and homocysteine in 
pwMS and to evaluate the effect of MS symptoms if 
deficiencies are addressed 
In Caucasian females’ serum  In Caucasian female’s serum iron and ferritin concentrations 
were significantly lower than controls After 6-month 
intervention of nutritional supplements improvement on EDSS, 
reduced homocysteine concentrations at 6 months 
Hon et al. used the same female sample which was divided into two groups: 31 female Caucasians* and 26 female Caucasians#. Five were excluded because they were using fatty acid supplements, interferon, or 
cortisone. 
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CO = Country; ST = Study Type; ZA = South Africa; ZW = Zimbabwe; KE = Kenya; UG = Uganda; CS = Cross-sectional study; PC = Perspective Cohort; RC = Retrospective Cohort, MS = Multiple 
Sclerosis; PwMS = persons with Multiple Sclerosis; EDDS = Expanded Disability Status Scale; RRMS = Remitting and relapsing MS; BMI = Body Mass Index; GC = Gas chromatography; FA = 
Fractional Anisotropy; DTI = Diffusion Tensor Imaging; RBC = Red Blood Cells; FA = fatty acid; MSRV = MS Retro virus; EBV = Epstein Barr Virus; HLA = human leukocyte antigen; CRP = C-reactive 
protein; SATS = Saturated fatty acids; CNS = Central nervous system; NEFA = non-esterified fatty acid; NRAMP-1 = natural resistance-associated macrophage protein-1; HH = hereditary 
haemochromatosis; OCT = Optical Coherence Tomography; RNFL = Retinal Nerve Fibre Layer; ON = Optic Neuritis; TMV = Total Macular Volume; %tfsat = percentage transferrin saturation; QoL = 
Quality of life . 
Citation, 
author, 
date 
CO ST Demographics Aims of the study Methodology Key findings 
Other 
(58) Roos 
2016 
ZA CS 19 pwMS (16 female); 11 Indian, 4 
Caucasian British, 3 Caucasian 
Dutch, 1 Mixed ancestry; 15 ZA 
born; 4 ZW born 
To determine the role and usefulness 
of OCT in a local cohort of MS patients 
 
PwMS being treated with interferon b-1B 
underwent OCT exam of both eyes. 
RNFL thickness and macular volume 
were measured and correlated with 
clinical disease characteristic, history of 
optic neuritis and level of disability 
 
No significant difference in mean RNFL in eyes with a 
history of ON and those without 
Eyes with a history of ON did have significantly thinner 
RNFL 
Strong correlation between TMV and RNFL 
No correlation between RNFL and disability scores 
(59) 
Shannon 
1994 
ZA CS 24 ZA pwMS (21 females) (22 
Caucasians; 2 Indian) 
To identify the deficits underlying 
observed behavioural performance 
difficulties regarding the behavioural 
sequelae accompanying pwMS 
Qualitative and quantitative assessment 
instruments used 
Two subgroups: 
Subgroup 1 displayed fatigability, information overload 
and disturbed fine control and integration of skilled motor 
movement 
Subgroup 2 displayed disturbed attention, concentration 
and tracking and disturbed executive skills  
(60) 
Herbert 
2018 
ZA CS 107 Caucasians ZA pwMS (93 
females) 
To investigate the relationship 
between FA and disability and blood 
iron parameters associated with FA 
and/or disability 
PwMS confirmed according to McDonald 
et al. Criteria. 11 of the females 
underwent DTI studies, EDDS 
assessment and MRI. Only EDSS ≤ 3 
and ≥6 grouped and data analysed. 
Control of 12 healthy females. 
 
 
 
 
Patients with high EDSS scores the mean FA was 
significantly lower than controls. Patients with low EDSS 
scores had similar mean FA values to controls. Positive 
association between FA and the iron parameters in all 
the white matter tracts. 
Whole patient group found inverse association between 
the EDSS and the %Tfsat showing reduced disability in 
the presence of higher blood iron parameters. Significant 
inverse association between disease duration and 
haemoglobin and %Tfsat 
(61) 
Temlett 
1988 
ZA CS 24 Caucasian ZA born pwMS (14 
females) 
To establish the diagnosis of MS in a 
group of patients with clinically 
acceptable criteria of the disease can 
be confirmed by MRI 
Using the criteria of Rose and Poser the 
pwMS subdivided in clinically definite, 
probable or possible MS and then 
underwent MRI 
9 clinically definite MS; 9 probable, 6 possible 
(62) 
Klugman 
2002 
ZA CS 30 ZA pwMS (29 Caucasian); 2:1 
female ratio 
To investigate the self-reports or 
perceptions of a group of ZA pwMS 
regarding the nature of any speech, 
language, hearing and swallowing 
difficulties experienced as well as the 
impact of these problems on QoL 
 
Cross-sectional survey  70% of pwMS experienced speech and/or language 
problems; 61.9% of the 70% felt the speech/language 
impacted significantly on their QoL. 50% of pwMS 
experienced swallowing difficulties; 53.4% of the 50% 
say it impacted their QoL. 
23.3% experienced hearing difficulties; 42.8% of these 
pwMS say hearing impacted their QoL 
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Figure 2.1 Flow chart of data synthesis 
 
Studies that could be grouped under the “aetiology” theme, focused on the human leukocyte antigen 
(HLA) presence in certain ethnic groups of pwMS and the presence of certain viruses such as measles 
and Epstein-Barr virus, (EBV) in pwMS as causes of MS. One study evaluated the link between 
homocysteine and obesity as risk factors for MS and another that looked at migrating from a high-risk 
area for MS to a low area of MS as a possible prevention for developing MS.  
The studies that were grouped under the ‘epidemiology’ theme, focused on the incidence of MS. The 
earlier studies on epidemiology by Dean,(44) Bird,(42,43) and Rosman,(45) only identified Caucasians 
with MS in SA but the later studies by Bhigjee,(28) and Modi,(13) though less prevalent, showed MS in 
all ethnic groups. There are also more people being reported with MS in all the countries that reported 
pwMS. The two studies in Kenya reported an increase in the incidence of black pwMS.(25,27)  
The studies grouped under the theme of ‘Haematology’ were all conducted in South Africa, and focused 
on blood parameters potentially involved in various physiological MS processes (e.g. demyelination). 
These factors were the involvement of fatty acids, phospholipids and cholesterol on the membranes of 
the red blood cells and the fluidity and permeability of the membranes. Two studies evaluated the 
association of EBV, Human herpesvirus-6 and varicella zoster virus as causative roles in the aetiology 
of MS.(49,51) Two studies evaluated the association of iron concentrations to certain genes in pwMS 
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compared to controls.(56,57) The only intervention study in this review focused on iron status, folate 
and homocysteine concentrations in pwMS. If any deficiencies in these concentrations were identified, 
these pwMS would be placed in an intervention group to address these deficiencies with either a 
multivitamin or specific iron or folate supplements.  
The studies grouped under the theme ‘other’, covered research in Optical Coherence Tomography 
(OCT);(58) neuropsychology;(59) imaging;(60,61) and perceptions of symptoms.(63) 
 2.4 Discussion  
To our knowledge, this is the first comprehensive scoping review of studies in pwMS that originate from 
sub-Saharan Africa. This review highlights that there is an increase in the number of reported cases of 
pwMS in sub-Saharan Africa, even though there have only been a few studies on the epidemiology of 
MS in sub-Saharan Africa in the last decade. Hence, it seems that despite increased access to 
diagnostic tools, and increased academic capacity, and potentially increased incidence of MS; interest 
in MS in the context of sub-Saharan Africa is meagre. The majority of the studies reviewed for this 
study, focused on the aetiology of MS. Aetiology of MS was of particular interest to earlier researchers 
due to the notion that MS was not present or less prevalent in black Africans. However, this thinking 
changed slowly over time as the increased access to diagnostic tools and understanding of MS 
improved with more research in the aetiology of MS. However, some important gaps in the existing 
body of evidence were identified that warrant future research.  
First, the aetiology of MS in sub-Saharan Africa is difficult to investigate due to the need for laboratory 
equipment and tests that many sub-Saharan countries would not be able to afford. Thus, the situation 
might represent a significant under diagnosing (and management) of MS in sub-Saharan Africa. To 
illustrate, a study by Langer-Gould et al. (64) did not find a different prevalence of MS amongst 
Caucasian and black males. Hence, the epidemiological differences reported in Africa, could above all, 
be related to access to resources. This may also partly explain why studies conducted with expensive 
equipment like neuroimaging were done in South Africa. Increased access to resources in other African 
countries may further increase our knowledge and understanding of MS in sub-Saharan Africa.  
Despite this limitation, there is evidence of an increase in the detection of MS in sub-Saharan Africa.(17) 
Yet, the most recent studies were conducted in 2008 (in South Africans with MS).(13) Hence, a second 
important gap relates to aetiology and how it relates to the actuality of research findings. To further 
illustrate, the studies from Kenya are from 2001,(27) and Uganda from 1980.(24) Hence, recent 
statistics on the incidence of MS across the entirety of sub-Saharan Africa are lacking. Nonetheless, 
the Atlas of MS has numbers of pwMS in sub-Saharan Africa which they located through key people 
investigating MS in a number of countries in sub-Saharan Africa.(17) A comparison of the Atlas data 
published in 2008 and 2013 indicates a higher prevalence of MS across many ethnic backgrounds. 
There are various reasons one may postulate for this finding, such as increased awareness and 
resources to diagnose MS in sub-Saharan Africa. Communicable disease like HIV, TB and more 
recently non-communicable diseases of lifestyle have been of higher priority in the context of mortality 
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and disability in sub-Saharan Africa. Logically, resources and funding are diverted to the study of these 
“colliding epidemics”.  
In the light of increasing incidence, prevalence, and awareness of MS in sub-Saharan Africa, there were 
very few studies on fatigue and lifestyle related factors on pwMS, which supports that a stronger focus 
on research for the management of MS in a sub-Saharan African context is warranted. While there is 
ample knowledge on the management of pwMS originating from western countries with a high 
prevalence of MS, it has been structurally shown in other medical conditions that simply trying to 
implement these evidence-based management strategies in a complex African setting are set-up for 
failure. Hence, a third important gap in the existing body of knowledge lies with the management of MS 
in the African (resource-limited) context. For example, a better understanding of physician awareness 
and patient referral schemes, availability of disease-modifying therapies, (low-cost yet effective) 
rehabilitation models, and more insight into the specific symptom “burden” of pwMS in various sub-
Saharan African contexts would be beneficial to health care practitioners dealing with pwMS in order to 
optimize care. 
2.4.1 Limitations 
There were certain limitations to this scoping review. First, the limited academic capacity, and 
awareness of MS in many sub-Saharan African countries, may lead to an underestimation of MS 
epidemiology. It can be questioned to what extent local research from sub-Saharan African countries 
find its way into established, English, peer-reviewed journals. Second, we excluded case-studies from 
this review that may contribute slightly that skewed picture. However, the number of case-studies was 
limited: three from Ethiopia, Senegal and Cameroon with single accounts of pwMS. 
2.4.2 Conclusions 
Research on MS originating from sub-Saharan Africa has largely been focussed on aetiology and 
epidemiological studies. No studies were found describing the symptom experiences and management 
of pwMS. Moving forward, in the light of increase awareness and resources to diagnose MS, it is 
recommended to shift focus to the patient symptom experience and management while in parallel create 
a better understanding on the epidemiology of MS across ethnicities. 
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CHAPTER 3 
A Cross-sectional online Study on the characteristics, comorbidities and 
symptoms experienced by individuals with Multiple Sclerosis in South Africa 
 
Abstract 
Background: The prevalence of Multiple Sclerosis (MS) in South Africa (SA) is low (4/5 per 100 000) 
and there is limited research on MS beyond the level of basic epidemiology. The profile of patients with 
MS (pwMS) in the northern hemisphere is well documented, and factors contributing to the health state 
of pwMS such as fatigue, depression, sleep issues, cognitive and motor function problems are well 
documented. However, it can be hypothesized that the relative contribution of these factors might be 
context specific. 
 
Objective and Methods: the objective of this study is to develop a profile of MS in SA, with the aims 
to gain insights into the various lifestyle factors that impact South African pwMS. A cross-sectional 
survey was sent out through the MS Society of South Africa to 1048 pwMS across the eleven provinces 
of SA in April 2017. The participants were asked to complete the survey within 24 hours from start to 
finish with no longer than a hour break between stopping for breaks. The participants were reminded to 
do the survey after two weeks and after four weeks if they had not completed it already. Outcomes were 
included across all domains of the International Classification of Functioning model (Health condition, 
Body Function, Activity, Participation, Environmental- and Personal factors). 
 
Results: 122 of 1048(11.6%) completed the survey (Age=4710 yr, Male(%)=14, disease 
duration=119 yr). PwMS were generally moderately disabled (30.2%) according to the Patient 
Determined Disease Steps. Comorbidity was frequent, with 39.3% of pwMS reporting three or more 
comorbidities. Detrimental lifestyle behaviour was prevalent with 64% of pwMS being inactive and 66% 
reported having smoked at some time in their lives. In contrast, fatigue assessed using the PROMIS 
fatigue short form was relatively low (30% severe fatigue). 
 
Conclusion: The characteristics and symptoms experience of pwMS in in SA was much in line with 
those for developing countries. A triad of poor lifestyle behaviour, low levels of physical activity, and 
high burden of comorbidity warrant future research. 
 
 
 
 
 
 
 
 
Stellenbosch University https://scholar.sun.ac.za
17 
 
3.1 Introduction  
The prevalence of Multiple Sclerosis (MS) in South Africa (SA) is low (4 to 5 per 100.000) relative to the 
worldwide prevalence which is 33 per 100.000.(13,14) However, it has also been reported that the 
incidence of MS in SA is increasing.(13) Yet, due to the low prevalence of MS in SA, there is a lack of 
research on MS beyond the level of basic epidemiology. A scoping review on original research 
originating from Sub-Saharan Africa in patients with Multiple Sclerosis(pwMS) identified thirty-three 
studies; with the predominant portion of these studies investigating the aetiology of MS, while only a 
handful studies (n=5) addressed a more clinical orientated topic (e.g. perceptions of pwMS, 
neuroimaging, neuropsychology). (See Chapter 2 of this thesis)  
 
The clinical characteristics, signs and symptoms of pwMS in the northern hemisphere is relatively well 
documented, and factors contributing to the health status of pwMS such as fatigue, depression, sleep 
issues, cognitive and motor function problems have been well studied. However, it can be hypothesized 
that the relative contribution of these factors might to some extent be context specific. In other words, 
the characteristics, symptoms and health state of pwMS could be dissimilar on a micro level (e.g. rural 
versus urban setting), macro level (e.g. latitude, exposure to vitamin D), as well as country-specific (e.g. 
medical insurance which gives patients access to private medical care vs the public health care system). 
Hence the objective of this study is to describe the characteristics and symptoms of pwMS in SA, with 
the aim to gain insight into these country-specific characteristics and symptoms experiences of pwMS 
living in SA, and in particular those that would warrant future research to optimize the health care and 
well-being of South African pwMS. 
 
3.2 Methods 
 
3.2.1 Study Design 
A cross-sectional online survey conducted through the MS Society of South Africa (MSSA) (Appendix 
C). This study was approved by the Health Research Ethics Committee, Stellenbosch University 
(N17/02/017) (Appendix B). The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) guidelines (Appendix F) were used in reporting this cross-sectional study.(64)  
 
There are currently 1050 pwMS affiliated to MSSA. A digital survey, using the REDCap (Research 
Electronic Data Capture, University of Stellenbosch, Cape Town, South Africa)  data collection 
platform,(65) was sent out to all MSSA registered pwMS across the eleven provinces of South Africa in 
April 2017. The aim was to recruit all known pwMS in SA according to the MSSA. The study sample 
would be determined by the responses received. PwMS received a link to complete the survey directly 
from the MSSA to ensure anonymity. PwMS were provided with standardised information and 
instructions before beginning the survey, and on accepting the information, provided digital informed 
consent. Reminders were sent out at two weeks and four weeks after the initial email, to encourage 
participation in the study if they had not done so already. The survey was estimated to take one hour 
to complete and the respondents were able to stop and save to complete the survey later but were 
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encouraged to complete the entire survey in a single day. The demographic characteristics of the pwMS 
that were assessed included: age (years); sex (male/female); ethnicity and 1st and 2nd line family 
background (due to the genetic component in the incidence of MS);(2) self-reported body weight (kg) 
and height (cm); which are used to derive the body mass index (BMI) and classified as underweight 
(<18.5); normal weight (18.5-24.9); overweight (25.0-29.9); obese (≥30.0).(66) 
 
3.2.2 Outcomes  
The descriptive measures were selected based on their reported relevance for pwMS and aligned with 
the International Classification of Functioning (ICF) model (see Figure 3.1).(67) The ICF model identifies 
three core components of functioning, namely body functions and structures, activities and participation. 
These components subsequently interact with a persons’ health condition as well as contextual factors 
(both environmental and personal). The respective outcome measures were chosen on pragmatic 
choice due to time to complete, the reported use in a SA context and together a comprehensive scope 
of the characteristics and experiences/perceptions of MS in SA. 
 
3.2.2.1 Health Condition  
The following outcomes were included under “Health condition”: type of MS, disease severity, time since 
diagnosis, and comorbidity profile. To determine self-report type of MS, the respondents were given a 
short lay-term description of each MS phenotype (e.g. relapsing – remitting, primary progressive). To 
determine the participant’s disability level, the Patient-Determined Disease Steps (PDDS) was 
used.(68) The PDDS has nine ordinal levels ranging between 0 (Normal) and 8 (Bedridden) and can 
be categorized as mild (0-2), moderate (3-5), or severe (6-8) disability.(68) A validated self-report 
questionnaire for comorbidity developed for MS was used including 37 secondary health conditions.(69) 
HIV/AIDS and Tuberculosis were added to this list due to their specific relevance for the South African 
setting. 
 
3.2.2.2 Body structure and function  
Body structure and function focuses on the physiological functions of the body’s systems (including 
psychological functions) and the anatomical parts of the body such as organs, limbs and their 
components.(67) To assess mobility and gait function, the MS Walking Scale-12 (MSWS-12) was used; 
a 12-item self-report questionnaire where the outcome is a score between 0 – 100. Higher scores 
indicate greater impact of MS on walking. Strong associations have been reported between the MSWS-
12 and other MS-related disability outcome measures (Expanded Disability Status Scale and Multiple 
Sclerosis Impact Scale – 29).(70,71) 
 
Cognitive function was assessed using the PROMIS Cognitive Ability Short Form (SF).(72) This 8-item 
short form uses a 5-point Likert scale (Never-Always) to assess patient-perceived functional abilities 
with regards to cognitive tasks. To calculate all the PROMIS scores, the guidelines from the PROMIS 
assessment centre’s scoring manual were used.(73) A higher PROMIS T-score represents more (e.g. 
more cognitive ability) of the specific concept that is measured. 
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Figure 3.1 ICF model for the characteristics of MS© 
 
 
3.2.2.3 Activity 
Activity, according to the ICF model, focuses on the execution of a task or action by an individual and 
the difficulties an individual may have in executing activities. Physical activity over the past 7-days was 
assessed using the International Physical Activity Questionnaire (IPAQ). The IPAQ comprises of 22 
questions over 5 different domains: work-related, transportation, housework, recreation and sitting. The 
responses to these 22-items are subsequently translated into metabolic equivalents (METs; i.e. energy 
expenditure) and MET minutes, and the sum of METs can be classified into three different levels of 
physical activity (inactive, minimally active and health enhancing active). These classifications have 
been reported to correspond well with objectively assessed step count.(74)  
 
3.2.2.4 Participation 
Participation evaluates the participant’s involvement in life situations and the problems an individual 
may experience in certain life situations. The ability to participate socially was assessed using the 
validated PROMIS Satisfaction with Participation in Social Roles Short Form (SF), which is a 8-item 
measure.(75) The ability to engage in social activities (e.g. “I have trouble doing all of the family activities 
that I want to do”) is rated on a 5-point Likert scale (Never to Always).(75) The response scores from 
the items are totalled and analysed in similar fashion as the PROMIS Cognitive Ability SF. A higher 
outcome (i.e. T-score) means a better perceived social participation.  
The EQ-5D-5L is widely accepted as a valid, responsive and short (5 items) tool to assess the general 
health-related quality of life relative to the general population.(76) The descriptive system has five 
dimensions: Mobility, Self-care, Usual activities, Pain/discomfort and Anxiety/depression each rated on 
a 5-point Likert scale (No problems – Extreme problems). The responses for each of these dimensions 
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are then aggregated into a weighted health index using a reference value set.(77,78) The descriptive 
dimensions are complemented by a single general health question using a 0 (worst health) to 100 (Best 
health) visual analogue scale. 
 
3.2.2.5 Contextual Factors 
Environmental factors included: sociodemographic context (i.e. rural / peri-urban / urban setting); and 
socioeconomic status (i.e., net household income expressed using Purchasing Power Parity (PPP; 
International dollar).(79) 
  
Personal factors included respondents’ experience of fatigue, anxiety, depression, sleep disturbances 
and health related behaviour (i.e. smoking and alcohol consumption). Fatigue, is one of the more highly 
frequent (>80%) reported disabling symptom experienced by pwMS.(80) The self-reported 
questionnaires used to assess fatigue are: the PROMIS Fatigue Short Form (SF); the Fatigue Severity 
Scale (FSS) and the Fatigue Scale of Motor and Cognition (FSMC). The PROMIS Fatigue SF is 8 items 
and the responses are rated on a 5-point scale ranging from ‘Never’ to ‘Always’ and are summed and 
transformed to a T-score metric. Higher scores indicate more fatigue.(81) The response scores from 
the items are totalled and analysed in similar fashion as the PROMIS Cognitive Ability SF. The FSS is 
9 items and has been known to assess the impact of fatigue on daily functioning;(82) The scale is a 7-
point Likert Scale where 1= Strongly Disagree and 7= Strongly Agree. The Score range is 1-7 and a 
higher score indicates more severe fatigue. To determine a score a mean score is calculated. Scores 
≥ 4 indicates severe fatigue.(83) The FSMC has 20 items, with separate domains for motor and 
cognitive aspects of fatigue.(84) The item responses are rated on a 5-point Likert Scale ranging from, 
“Does not apply at all” to “Applies completely”. The score range is from 20-100 for an overall sum fatigue 
score. There is a score for cognitive fatigue and physical fatigue. The cut-off values for the summed 
score is ≥ 63 Severe fatigue, ≥ 53 Moderate fatigue and ≥ 43 Mild fatigue; the Cognitive Score is ≥ 34 
Severe fatigue, ≥ 28 Moderate fatigue and ≥ 22 Mild fatigue; and Physical Score is ≥ 32 Severe fatigue, 
≥ 27 Moderate fatigue and ≥ 22 Mild fatigue.(84) These measures, validated in patients with MS, 
combined, provide a comprehensive assessment (severity, impact, motor, and cognitive) of one of the 
most debilitating symptoms of patients with MS. Due to fatigue’s subjective nature and the lack of 
consensus regarding definition, including multiple complementary measures to assess fatigue is 
recommended.(85) The Hospital Anxiety (HADS-A; 7 items) and Depression (HADS-D; 7 items) scale 
was used to assess the presence of anxiety and depressive symptoms respectively.(86) Each item is 
scored 0 to 3, and a summed score of 0 to 7 is defined as ‘Normal’, 8 to 10 defined as a ‘Mild’, 11 to 14 
as a ‘Moderate’ and 15 to 21 as a ‘Severe’ case of anxiety or depression respectively.(87) Finally, sleep 
disturbances were assessed using the PROMIS Sleep Disturbance Short Form (SF) which is an 8-item 
measure, and analysed in line with the other PROMIS measures.  
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Smoking status was assessed using three items from the Behavioural Risk Factor Surveillance 
Survey.(88) A smoker was defined as having smoked ≥100 cigarettes in his/her lifetime. Alcohol intake 
was assessed with the AUDIT-C.(89) A score of ≥4 (men) or ≥3 (women) was considered positive for 
an increased risk for hazardous drinking, active alcohol abuse, or alcohol dependence.(90) 
 
3.2.3 Data-analysis  
A Shapiro-Wilk’s test (p>0.05) and visual inspection of their histograms, normal Q-Q plots and box plots 
with skewedness and kurtosis were used to analyse if the data were normally distributed.(91) For data 
that were normally distributed, mean and 95% confidence level (95%CI) are reported. For data that 
were not normally distributed median and interquartile range (IQR) are presented. Descriptive statistics 
were used to characterise the cohort of pwMS with respect to all the outcomes presented in the survey. 
All analyses were conducted using IBM SPSS® version 25 software (IBM SPSS Statistics, IBM 
Corporation, Armonk, New York). A p-value >0.05 was considered statistically significant. 
 
3.3 Results 
 
3.3.1 Demographics 
The survey was sent out to 1050 pwMS across all eleven provinces of South Africa. The survey was 
not delivered to two email addresses therefore, 1048 pwMS received the survey. There were 122 pwMS 
(11.6%) that responded to the survey of which 84 completed all the questions in the survey. Therefore, 
the sample size was 122 which was determined by the number of respondents to the survey. The 
demographic findings are summarised in Table 3.1, outcomes on the three domains of functioning in 
Table 3.2, and contextual factors in Table 3.3. The majority of the respondents were Caucasian (95%), 
and female (ratio of 6:1) with a mean age of 47 years (95%CI 46 to 49), and a median BMI of 28.9 (IQR 
17.8-56.8). Out of the 122 respondents, 70% were classified as either overweight or obese according 
to the defined weight categories. The percentage of pwMS presenting with relapsing remitting MS was 
68.1%, followed by secondary progressive MS (20.7%), and primary progressive MS (11.2%). The 
median PDDS score was 2 (IQR 1 to 3), and subsequently 30.2% of the respondents could be classified 
as moderately disabled. The percentage of respondents reporting no physical comorbidities was 31.1%, 
while 21.3% reported one, 8.2% reported two and 39.3% reported three or more comorbidities. The 
most frequent comorbidities reported were depression (36.1%), high blood pressure and high 
cholesterol (20.5%) respectively, migraines (15.6%) and anxiety disorders (13.9%). See Appendix D for 
a full description of the comorbidities assessed and reported. 
 
3.3.2 The three domains of functioning (Body structure and function, activity and participation) 
The median score of the MSWS-12 was 50 (IQR 0-100) reflecting a wide array of walking ability within 
the sample. The majority of the respondents (87.2%) fell within normal limits of cognitive abilities, as 
indicated by a median score of 44 (IQR 27 to 65) on the PROMIS Cognitive Abilities Scale and 
respective classification. The median total MET minutes was 594 (IQR 0-14.385) with 63.7% of the 
respondents categorised as inactive and 5.5% were engaging in health enhancing activity. The mean 
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score for the PROMIS Satisfaction with Participation in Social Roles scale was 55 (95%CI 53 to 57), 
and 49.4% of the respondents fell within normal limits of social participation while 6.7% struggled 
severely with social participation. The median index value for the EuroQol EQ-5D-5L was 0.6 (IQR -0.2 
to 1.0). The mean EQ VAS score for general health was 57.5 (95CI 52.4 to 62.6). 
 
3.3.3 Contextual Factors:  
 
3.3.3.1 Environmental  
Geographically, most respondents were living in either the Western Cape Province (38.5%), Gauteng 
(26.5%) or Free State (15.6%). Half of respondents are residing in an urban (50.4%) area, 39.5% in a 
peri-urban, and 10.1% in a rural context. With respect to socio-economic profile, 13.4% of the 
respondents received a monthly household income within the upper middle and higher bracket. In 
contrast, 2.5% of the respondents received a household income within the lowest bracket. The 
emerging middle to lower middle-income bracket had the highest pwMS at 37%. 
 
3.3.3.2 Personal factors 
The PROMIS Fatigue SF median score was 59 (IQR 33 to 78). Additionally, based on established cut-
off values, 41.1% of the respondents were classified as moderately fatigued while 30% of the 
respondents classified as severely fatigued. The FSS median score was 5.17 (IQR 1-7) with 73.9% of 
the respondents graded as severely fatigued. The FSMC median scores were 39 (IQR 10-50) for the 
cognitive domain, 41 (IQR 13-50) for the physical domain, and 78.5 (IQR 23-100) for the sum score. 
The cut off values for FSMC Cognitive, classified 68.9% of the respondents with severe cognitive 
fatigue, 82.2% with severe physical fatigue and 78.9% with an overall severe fatigue. The mean HADS 
score was 17.6 (95%CI 16.2 to 19.1). The mean anxiety score was 8.8 (95% confidence level 7.9-9.8). 
The mean depression score was 8.8 (95%CI 8.2 to 9.5). The PROMIS Sleep Disturbance mean score 
was 53 (95%CI 50 to 55) and 27.2% have moderate to severe sleep disturbances while 52.3% reported 
to have minimal sleep disturbances. With respect to alcohol use, 32.3% of the respondents scored 
positive on the Alcohol Use Disorders Identification Test (AUDIT-C). With respect to smoking, 65% of 
the respondents were considered smokers. 
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Table 2.1: Demographic Variables and Clinical Characteristics of Persons with Multiple 
Sclerosis in South Africa 
 
Demographic Characteristics   
Age (yrs) (n=122) 47 (46-49)# 
Height (cm) (n=100) 166.8 (165.2-168.3)# 
Weight (kg) (n=100) 80.4 (76.8-83.9)# 
BMI (n=100) 28.9 (17.8-56.8)* 
Categorical Variables N (%) 
Sex (n = 122)  
- Female 105 (86.1) 
- Male 17 (13.9) 
Ethnicity (n = 122)  
- White 116 (95.1) 
- Mixed ancestry 3 (2.5) 
- Asian/Indian 2 (1.6) 
- Black African 1 (0.8) 
Marital Status (n=119)  
- Living with a partner 84 (70.6) 
- Single 21 (17.6) 
-  Divorced 10 (8.4) 
-  Widowed 4 (3.4) 
BMI (n=100)  
-  Underweight 4 (4) 
-  Normal 26 (26) 
-  Overweight 28 (28) 
-  Obese  42 (42) 
Continuous Health Condition Variable  
Time since diagnosis (yrs) (n=116) 7 (1-38)* 
PDDS (n=116) 2 (1-3)* 
Categorical Variables N (%) 
Type of MS (n=116)  
- RRMS 79 (68.1) 
- SPMS 24 (20.7) 
- PPMS 13 (11.2) 
PDDS (n=116)  
- Mild 55 (47.4) 
- Moderate 35 (30.2) 
- Severe 26 (22.4) 
Number of comorbidities (n=122)  
- None  38 (31.1) 
- One comorbidity 26 (21.3) 
- Two comorbidities 10 (8.2) 
- Three or more comorbidities  48 (39.3) 
# = mean (95%CI = 95% confidence interval). * = median (IQR = Interquartile range). BMI = Body Mass Index. 
RRMS = relapsing-remitting multiple sclerosis. SPMS = secondary-progressive multiple sclerosis. PPMS = 
primary-progressive multiple sclerosis. PDDS = Patient Determined Disease Steps scale 
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Table 3.2: The Body Structure, Activity, Social Participation and Environmental Outcomes in 
Persons with Multiple Sclerosis in South Africa 
Body Structure Variables   
MSWS-12 (n=84) 50 (0-100)* 
PROMIS cognitive abilities scale (n=94) 44 (27-65)* 
Activity Variable   
IPAQ Total Met minutes (n=91) 594 (0-14385)* 
Participation Variables  
EQ-5D-5L Index value (n=90) 0.6 (-0,2-1,0)* 
EQ VAS score (n=90) 57.5 (52,4-62,6)# 
PROMIS Social (n=90) 55 (53-57)# 
Categorical Variables N (%)  
PROMIS cognitive categories (n=94)  
- Within normal limits 82 (87.2) 
- Mild 6 (6.4) 
- Moderate 6 (6.4) 
- Severe 0 
IPAQ (n=91)  
- Inactive 58 (63.7) 
- Minimally active 28 (23) 
- Health enhancing active 5 (5.5) 
PROMIS Social* (n=89)  
- Within normal limits 44 (49.4) 
- Mild 22 (24.7) 
- Moderate 17 (19.1) 
- Severe 6(6.7) 
Environmental Variables N (%) 
- Setting (n=119)  
- Urban 60 (50.4) 
- Peri-urban 47 39.5) 
- Rural 12 (10.1) 
Income Level (PPP) (n=119)  
- Upper middle and higher ($23.990->$113.433) 16 (13.4) 
- Emerging middle to lower middle ($10679-$23990) 44 (37) 
- Low emerging middle ($5774-$10679) 13 (10.9) 
- Second lowest ($4030-$5774) 9 (7.6) 
- Lowest (<$2672) 3 (2.5) 
- Didn’t want to disclose 34 (28.6) 
# = Mean (95%CI = 95% confidence interval). * = Median (IQR = Interquartile range). MSWS-12 = 
Multiple Sclerosis walking scale. IPAQ = International Physical Activity Questionnaire. EQ-5D-5L = 
EuroEqol EQ-5D-5L. EQ VAS=EuroQol Visual Analogue Scale. PROMIS Social = PROMIS   
Satisfaction with Participation in Social Roles. PPP = Purchasing Power Parity 
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Table 3.3: The Fatigue, Social Participation, Sleep and Substance Abuse Outcomes of the 
Persons with Multiple Sclerosis in South Africa 
Personal Variable  
PROMIS fatigue (n=90) 59 (33-78)* 
FSS (n=88) 5.17 (1-7)* 
FSMC Cognitive (n=90) 39 (10-50)* 
      Motor (n=90) 41 (13-50)* 
      Sum Total (n=90) 79 (23-100)* 
HADS-D (n=90) 8.8 (8.2-9.5)# 
HADS-A (n=90) 8.8 (7.9-9.8)# 
HADS Total (n=90) 17.6 (16.2-19.1)# 
PROMIS Sleep (n=88) 53 (50-55)# 
Categorical Variables N (%) 
PROMIS fatigue (n=90)  
- Within normal limits 15 (16.7) 
- Mild 11 (12.2) 
- Moderate 37 (41.1) 
- Severe 27 (30) 
FSS (n=88)  
- Score <4 23 (26.1) 
- Score >4 65 (73.9) 
FSMC Cognitive (n= 90)  
- Within normal limits** 11 (12.2) 
- Mild 6 (6.7) 
- Moderate 11 (12.2) 
- Severe 62 (68.9) 
FSMC Motor (n=90)  
- Within normal limits** 6 (6.7) 
- Mild 4 (4.4) 
- Moderate 6 (6.7) 
- Severe 74 (82.2) 
FSMC Sum Total (n=90)  
- Within normal limits** 8 (8.9) 
- Mild 6 (6.7) 
- Moderate 5 (5.6) 
- Severe 71 (78.9) 
HADS-D (n-90)  
- Within normal limits 31 (34.4) 
- Mild 29 (32.2) 
- Moderate 28 (31.1) 
- Severe 2 (2.2) 
HADS-A (n=90)  
- Within normal limits 40 (44.4) 
- Mild 17 (18.9) 
- Moderate 23 (25.6) 
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- Severe 10 (11.1) 
Categorical Variables continued N (%) 
PROMIS Sleep (n=88)    
- Within normal limits 46 (52.3) 
- Mild 18 (20.5) 
- Moderate 20 (22.7) 
- Severe 4 (4.5) 
Substance use   
Alcohol (n=99)   
- Female ≥3 30 (30.3) 
- Male ≥ 4 2 (2) 
Smoking (n=100)   
- Smoker 63 (63) 
- Non-smoker 37 (37) 
 
# = mean (95%CI = 95% confidence interval). * = median (IQR = Interquartile range). HADS-D = Hospital Anxiety 
and Depression scale – Depression. HADS-A = Hospital Anxiety and Depression Scale – Anxiety. ** = FSMC 
does not have “within normal limits” as part of its cut offs so to make it easier for comparison with PROMIS 
Fatigue SF, “within normal limits” were added to scores that fell below the cut off set for mild fatigue. 
 
 
3.4 Discussion 
This study is the first cross-sectional study in SA to focus on various clinical features and outcomes, 
structured according to the ICF model. The survey response rate was low which means that there is 
uncertainty as to whether the results are able to be generalised to the South African MS population of 
to the global MS population. The results do give a good indication as to symptoms and characteristics 
experienced by pwMS in SA and further investigations into these aspects need to be considered. 
 
Two findings that show discrepancy between this sample and the global population of MS is the female 
to male ratio and the mean age of pwMS. The female to male ratio in this study was found to be 6:1 
whereas the global ratio of female to male is 2:1.(17) The mean age of pwMS globally is 30 years, (17) 
the mean age in this study was 47 years. The large difference in the female to male for pwMS in SA is 
not fully understood as there could be a number of reasons such as there are more females with MS in 
SA, or more females responded to the survey but as to whether this finding can be applied to the general 
population of MS in SA is uncertain and further studies are needed to confirm the true number of females 
to males with MS in SA. The older mean age of pwMS in comparison to the global mean age of 30 
years is also an interesting finding but may be due to lack of understanding of MS and diagnosis may 
have been delayed. This too would need to be investigated further. 
 
The results indicate a high presence of comorbidity (~40% reported three or more) with the most 
frequent comorbidities reported: depression (36.1%), high blood pressure and high cholesterol (20.5%), 
migraines (15.6%) and anxiety disorders (13.9%) respectively. In addition, there was a high presence 
of adverse lifestyle behavioural factors including smoking, alcohol use, and physical inactivity. Only 5% 
of pwMS in this study were able to report a level of physical activity that can be considered health-
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enhancing. Despite the high prevalence of these risk factors, levels of satisfaction with social 
participation were relatively high. 
 
Adverse lifestyle behaviour and comorbidity 
The comorbidity profile described in this study was in line with previous reports on pwMS,(92,93) which 
also showed depression, high blood pressure and high cholesterol concentrations as the leading 
reported comorbidities or risk factors. Mental comorbidities have a higher prevalence among pwMS 
than the general population,(94) with depression being recognized as the most common mental 
comorbidity in MS with a lifetime prevalence as high as 50%.(95) Unfortunately, mental comorbidities 
in MS often remain underdiagnosed and undertreated especially in lower socioeconomic status (SES) 
pwMS.(96) This is an important consideration for the SA context as 55.5% of the general population of 
SA have a low SES.(97) Ataguba et al. found there is a strong and persistent negative relationship 
between levels of socioeconomic status and psychological distress among the general SA 
population.(98) In this study only 2.5% of the respondents reported having a low SES. This may mean 
that this sample isn’t a true representation of the socioeconomic groups within SA and that there may 
be a lot more South Africans with MS that the MSSA are not aware of as the pwMS may not have 
access to the internet or the pwMS are not aware of organisations such as the MSSA. Or there are less 
pwMS in low SES due to the high ethnicity driven and vast inequality in SA, as well as the higher risk 
for MS is in Caucasian people who in majority do not have a low SES. More research is needed to 
assess pwMS in lower SES in SA as they are probably dealing with high levels of psychological distress. 
 
This high prevalence of comorbid disease in pwMS is a growing concern for health care professionals 
due to the adverse impact that is associated with comorbidities.(99) Marrie et al. has found an 
association between the presence of (physical) comorbidities and time between MS symptom onset 
and diagnosis.(100) In addition, these patients were more likely to have severe disability at diagnosis, 
even after accounting for diagnostic delays, and subsequently increased health-care 
utilization.(100,101) Comorbidities are also associated with higher mortality rates in MS.(102) Marrie 
suggests two important considerations for dealing with comorbidities in pwMS, which would be useful 
in the SA context; firstly health care professionals should be encouraged to timely recognise these 
conditions when they first become noticeable so that initiating effective treatment of these conditions 
would prevent the adverse effects of these conditions on MS.(99)  
 
And secondly, probably one of the best ways to address comorbidity in MS may be to prevent it 
altogether especially the modifiable health behaviours such as smoking, risky alcohol use, physical 
inactivity, and obesity.(99) These risky health behaviours are negative factors for several common 
comorbidities in MS, including hypertension, diabetes, hyperlipidemia, ischemic heart disease, cancers 
and chronic lung disease.(92,93,103) PwMS that have hypertension and hypercholesterolemia, were 
associated with more rapid self-reported disability progression and often needed assisted walking 
devices sooner than those without these conditions.(104)  
 
Stellenbosch University https://scholar.sun.ac.za
28 
 
This study shows a high prevalence of adverse, modifiable, risk factors specifically, in South African 
pwMS. Smoking is associated with an increased risk of chronic diseases such as stroke, cancer, and 
osteoporosis and is a possible risk factor for MS.(105) In the general SA population, 28.8% smoke,(106) 
where as in this study 63% of the pwMS smoke. Excessive alcohol intake has been found to be inversely 
associated with progression of disability in relapsing-onset MS.(107) Only 11% of the general SA 
population have an alcohol disorder,(106) where as 32% of the pwMS reported an alcohol disorder. 
This risky behaviour does raise concerns of the potential consequences of smoking and alcohol use 
disorders in pwMS and these concerns need to be addressed. The fact that the prevalence of smoking 
and alcohol disorders are higher in the pwMS compared to their healthy counterparts is even more 
reason for these risky behaviours to be addressed.  
 
As to the reasons why the pwMS have a higher prevalence of risky behaviour than the general 
population, this may be due to coping mechanisms to try to deal with their illness but no matter the 
reason, pwMS need to be advised on the risks and long term effects of smoking and alcohol abuse on 
the progression of MS. Only 5% of the respondents reported doing any health enhancing physical 
activity. This means that more than 86% of the respondents were doing very little or no physical activity. 
In comparison; it has been found that 47.1% of the general SA population are inactive.(108) In pwMS, 
physical inactivity is associated with increased risks of overweight and obesity, reduced aerobic 
capacity, loss of muscle strength, diabetes, colon cancer, hypertension, and premature death from 
cardiovascular disease.(109) Educating and making pwMS aware of the outcomes of these risky 
behaviours needs to be a focus for pwMS living in SA. 
 
Fatigue and Cognitive function 
It was interesting to note that 87.5% of the respondents of this survey placed within the normal limits 
for the PROMIS Cognitive Abilities Scale. This is in contrast to previous studies that have shown that 
~50% of pwMS report cognitive dysfunction already early-on in the disease course.(112,113) It has to 
be noted that, despite validation work of the  PROMIS cognitive abilities scale done on pwMS,(72) the 
PROMIS cognitive abilities scale has not been widely used in pwMS. Studies that have reported higher 
levels of cognitive dysfunction generally used the Minimal Assessment of Cognitive Function in MS 
(MACFIMS),(111) or the Rao Brief Repeatable Neuropsychological Battery (BRNB).(112) Hence, it is 
important  to consider that the PROMIS cognitive abilities scale is less sensitive to, the often subtle, 
cognitive dysfunction compared to other validated tools. A particular drawback of the PROMIS Cognitive 
Abilities scale is that cut-off values are based on the general population of the United States of America 
which may lack external validity to other, in particular non-Western, study populations. 
 
Fatigue is one of the most common and often most debilitating symptom of MS, affecting as much as 
70 - 80% of pwMS.(80,113) In this study only 30% of the respondents showed they had severe fatigue 
and 53.3% were mild to moderately fatigued on the PROMIS Fatigue SF. The PROMIS Fatigue SF is 
considered a more unidimensional fatigue scale compared to its counterparts (e.g. FSMC).(114) The 
FSMC categorised 78.9% of the pwMS as severely fatigued and the FSS had 73.9% as severely 
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fatigued. There is a discrepancy in the categorising of pwMS that are severely fatigued between the 
PROMIS Fatigue SF and the FSMC and FSS. The FSMC and FSS had similar percentages in 
categorising severely fatigues pwMS. The PROMIS Fatigue SF showed the largest difference. Such 
discrepancies may hamper diagnosis of disabling fatigue in both a clinical and research context. Heine 
and de Groot, question the available research on assessing severe fatigue in pwMS and then using that 
assessment in intervention studies.(115) They suggest that the evidence is not strong enough to 
support the treatment of fatigue. This poor research may be using questionnaires which are not 
classifying pwMS correctly for severe fatigue. There is a need for research that looks into the cut-off 
points for severe fatigue so that if a pwMS scores severely fatigued on one questionnaire then they are 
also likely to be categorised as severely fatigued on another. We have attempted to answer this 
question in Chapter 4 of this thesis. 
 
Studies have found that there is a link between poor sleep and fatigue,(116–118) but in this study sleep 
disturbance did not appear to be a problem for majority of the participants. This link between sleep and 
fatigue needs to be further investigated in future studies in the SA context. The PROMIS short forms 
were used to assess cognitive abilities, fatigue and sleep disturbance in this study. All three forms 
showed differing results to other studies using these forms and favoured pwMS in SA having fewer 
symptoms i.e. fatigue, sleep issues and cognitive dysfunction. This finding needs to be investigated 
further as the PROMIS has a unique characteristic in that the scores of PROMIS measures are reported 
on a T- score metric that is anchored to mean score levels in the healthy general population of the 
United States of America. This interpretation may not be suitable for the South African context and 
requires further investigation. 
 
Social participation 
Previous studies have highlighted the importance of optimizing societal participation in pwMS. We 
hypothesized that for instance limited public transport, access to rehabilitation medicine, and other 
factors might hamper societal participation of pwMS in SA. However, based on the findings from the 
PROMIS Satisfaction with Participation in Social Roles questionnaire used in this study, participants 
reported above average satisfaction. It is known that pwMS have very low levels of satisfaction with 
participation in social roles.(119) There are a potential number of reasons to explain this difference 
found between this study and other studies. Majority of the pwMS came from a higher SES and most 
affluent people in SA have at least one motor vehicle. This would make traveling and having 
independence to socialise more convenient than having to rely on public transport. In Europe and other 
first world countries, public transportation is the main means of traveling and may be rather daunting 
for pwMS to have to utilise them on their own. Another reason that the SA pwMS showed higher levels 
of satisfaction with participation in social roles may be due to the scores being reported on a T- score 
metric that is anchored to mean score levels in a healthy general population of the United States of 
America. Again, further investigations are needed. 
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3.4.1 Limitations 
This study had some limitations, in addition to the conventional limitations for a cross-sectional survey 
(e.g. self-reported, no causal inference). In particular in the South African context (e.g. limited access 
to internet, limited awareness of a MS society), there may have been some selection bias. First, one 
may query the outreach of an MS society in rural and socio-economic challenging regions. In addition, 
there might be some under diagnosis of MS in some parts of the country. For instance, Modi et al. 
suggested that there are traditional myths among clinicians in SA that MS is not a “black population 
disease” and a black patient that presents with an apparent MS phenotype is investigated for possible 
alternative explanations and often left with an unclear diagnosis or idiopathic/nonspecific CNS 
demyelination.(19) This may contribute to the relative low prevalence of non-Caucasian participants in 
this study. Finally, it is unclear to what extent the digital means of surveying the pwMS reached the less 
privileged percentage of South African pwMS. This would be more applicable for pwMS living in a rural 
area as these areas are very often research and resource constraint settings. However, despite these 
limitations, the ethnic profile and urban to rural distribution of participants in this study was in line with 
previous reports.(13,28) The PROMIS cognitive ability scale is a limitation due to it not being used 
widely in studies on pwMS and may be less sensitive to cognitive abilities in pwMS and that the study 
population is the general population of the United States of America which may not be applicable to 
pwMS in SA or any other country until it has been validated. 
 
3.4.2 Conclusions 
To the best of our knowledge, this study is the first to extensively report the symptom experience of 
pwMS in SA. A triad of poor lifestyle behaviour, low levels of physical activity, and high burden of 
comorbidity is concerning and warrants future research. Increasing awareness amongst patients and 
health care professionals within the SA public and private medical setting with respect to lifestyle risk 
factors, comorbidity, and the impact of these on pwMS is called for. One of the symptoms that needs 
further investigation is pwMS that are affected by severe fatigue. Including pwMS that have severe 
fatigue in intervention studies will help improve the management of fatigue in pwMS. Studies have not 
shown clearly defined levels of fatigue or have not made it an inclusion criteria and so this may affect 
fatigue management programmes. Chapter 4 of this thesis attempts to address the need for cut off 
values for severe fatigue in the questionnaires used to assess fatigue which will then hopefully assist 
with including pwMS that have severe fatigue.
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CHAPTER 4 
Agreement between three self-report questionnaires to determine severe fatigue in Multiple 
Sclerosis – a cross-sectional online study 
Abstract 
Background: Fatigue, especially disabling fatigue, affects between 70% - 80% of patients with Multiple 
Sclerosis (pwMS). Fatigue is a subjective construct that is difficult and complex to assess. It has been 
suggested that its entirety can only be evaluated using multiple self-report measures. Some fatigue 
questionnaires have defined cut-off values to classify whether a person has severe fatigue, moderate 
fatigue or fatigue within normal limits.  Identifying pwMS that have severe fatigue has an important role 
in research. Including pwMS that have severe fatigue in intervention studies will help improve the 
management of fatigue in pwMS. However, in the context of the suggested use of multiple fatigue 
measures, this raises the following questions: how well the previous reported cut-off values of various 
fatigue measures align, and how can researchers ensure that only patients with a specific level of 
fatigue are included, independent on the choice of fatigue measures? 
 
Aim and Methods: the aim of this study is: i) to determine the agreement between the reported cut-off 
values for categorising severe fatigue in three commonly used fatigue questionnaires, and ii) to 
determine new cut off values to classify a participant as severely fatigued across all three questionnaires 
(e.g. 100% agreement). The data from the fatigue questionnaires from the cross-sectional survey done 
in chapter 3 were analysed to answer these questions. The three questionnaires used were: The 
Fatigue Severity Scale (FSS), The Fatigue Scale for Motor and Cognitive Functions (FSMC) and the 
PROMIS Fatigue Short Form (SF). 
 
Results: 122 of 1048(11.6%) completed the survey (Age=4710 yr, Male (%)=14, disease 
duration=119 yr). The FSS and FSMC categorised 73.9% and 78.9% respectively as severely 
fatigued. The PROMIS Fatigue SF categorised only 30% as severely fatigued. Using Cohen’s Kappa, 
a significantly moderate agreement was found between FSS and FSMC, (k = 0.563, p = 0.000), and 
not the PROMIS Fatigue SF. Cut-off values of 5.8 out of 7 for the FSS would provide 100% certainty 
that the “hypothetical” patient with these values would have qualified as severely fatigued on the FSMC. 
Conversely, a value 88.5 out of 100 for FSMC would provide 100% certainty that this same patient 
would have qualified as severe fatigued on the FSS. 
 
Conclusion: We argue for higher than the conventional cut-off values for indication of the presence of 
severe fatigue are used in the further study of fatigue specifically, to facilitate more accurate estimates 
of the effect of fatigue management programs. 
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4.1 Introduction 
Disabling fatigue affects between 70% - 80% of patients with Multiple Sclerosis (pwMS).(80,113) 
Despite the high incidence of pwMS that experience disabling fatigue, treatment of the fatigue remains 
difficult and the overall understanding of MS fatigue is far from complete.(120) There are multiple 
definitions for fatigue. A commonly used definition by the Multiple Sclerosis Council for Clinical Practice 
Guidelines considers fatigue as a "subjective lack of physical and/or mental energy that is perceived by 
the individual or caregiver to interfere with usual and desired activities".(121) Alternatively, Mills and 
Young suggest that fatigue should be defined as “reversible, motor and cognitive impairment with 
reduced motivation and desire to rest, either appearing spontaneously or brought on by mental or 
physical activity, humidity, acute infection and food ingestion”.(122) Aaronson et al. proposed the 
following definition of fatigue; “The awareness of a decreased capacity for physical and/or mental 
activity due to an imbalance in the availability, utilization, and/or restoration of resources needed to 
perform activity”.(123) These definitions share that fatigue is a subjective feeling experienced by the 
pwMS and impacts “performance or capacity” over time. One may distinguish chronic from acute 
fatigue, where the latter follows from a temporary circumstance such as physical activity or heat 
sensitivity,(83,121) whereas chronic fatigue is defined as, “fatigue present for any amount of time on 
50% of days for more than six weeks, which limits functional activities or quality of life”.(121)  
A second distinction relates the working mechanism behind the experience of fatigue, being primary or 
secondary fatigue. Primary fatigue is linked to the pathological process of MS itself (e.g. muscle 
weakness, cognitive reserve) whilst secondary fatigue is due to the chronic effects of MS (e.g. 
medications, insomnia or depression).(83,121) Assessing fatigue is therefore difficult and complex due 
to its multifaceted and subjective construct; and it has been suggested that its entirety can only be 
evaluated using multiple self-report measures (e.g. Fatigue Severity Scale [FSS], Fatigue Scale for 
Motor and Cognitive Function [FSMC]).(8) Due to fatigue’s subjective and multidimensional character, 
including multiple complementary measures to assess and measure fatigue is recommended.(85)  
Some fatigue questionnaires have defined cut-off values to classify whether a person has severe 
fatigue, moderate fatigue or fatigue within normal limits.  Identifying pwMS that have severe fatigue has 
an important role in research. Including pwMS that have severe fatigue in intervention studies will help 
improve the management of fatigue in pwMS. A Cochrane review by Heine et al.(124) found that non-
pharmacological interventions often have not been studied in patients with well-defined levels of fatigue, 
and in addition, fatigue is often not an inclusion criterion or primary outcome. This may lead to an 
underestimation of the true effect on fatigue of those and other fatigue management 
programs.(115,124) Only including patients with severe fatigue may be a means to increase the 
methodological quality of studies in the future. However, in the context of the suggested use of multiple 
fatigue measures, this raises the following questions: how well the previous reported cut-off values of 
various fatigue measures align, and how can researchers ensure that only patients with a specific level 
of fatigue are included, independent on the choice of fatigue measures?  
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To answer these questions, the aim of this study is: i) to determine the agreement between the reported 
cut-off values for categorising severe fatigue in three commonly used fatigue questionnaires, and ii) to 
determine new cut off values to classify a participant as severely fatigued across all three questionnaires 
(e.g. 100% agreement). 
 
4.2 Methods 
 
4.2.1 Study Design 
The fatigue questionnaires data from the cross-sectional online survey through the MS Society of South 
Africa (MSSA) that was used in Chapter 3 were analysed to answer the questions for this chapter. This 
study was approved by the Health Research Ethics Committee, Stellenbosch University (N17/02/017).  
 
A digital anonymous survey, using the REDCap (Research Electronic Data Capture, University of 
Stellenbosch, Cape Town, South Africa) data collection platform,(65) was sent out to all MSSA affiliated 
(1050) pwMS across the eleven provinces of South Africa. Participants provided digital informed 
consent prior to starting the survey. Reminders were sent out at two weeks and four weeks after the 
initial invitation. The survey was estimated to take one hour to complete, and participants were able to 
stop and save, but were encouraged to complete the entire survey in a single day.  
 
A detailed description of the outcomes included in this survey is reported elsewhere (See chapter 3 of 
this thesis). The following descriptive characteristics of the pwMS are included: age (years), sex 
(male/female), ethnicity , self-report type of MS, time since diagnosis (years), time since symptom onset 
(years), and Patient-Determined Disease Steps (PDDS).(68) The PDDS has nine ordinal levels ranging 
between 0 (Normal) and 8 (Bedridden) and can be categorized as mild, moderate, or severe 
disability.(68) 
 
The three fatigue questionnaires were chosen for the different aspects of fatigue they assess as well 
as their reported psychometric properties (e.g. validity, reliability).  
 
The Fatigue Severity Scale (FSS): 
The FSS measures the impact of fatigue on specific types of functioning, assesses the severity of 
fatigue symptoms and its impact on an individual’s daily functioning during the past week.(125) It has 
been determined to be sensitive to fatigue changes over disease progression or due to treatment.(126) 
The FSS, due to its strong psychometric properties, sensitivity to change and being unidimensional in 
its measurement of fatigue plus its internal consistency and stability over time makes it a strong 
candidate as the gold standard of measuring fatigue especially in MS. The FSS has been shown to 
differentiate between subgroups of patients with MS, chronic fatigue syndrome, and primary 
depression.(127)  The FSS has 9 items concerning respondent’s fatigue, e.g., how fatigue affects 
motivation, exercise, physical functioning, carrying out duties, interfering with work, family, or social life 
and has been known to assess the impact of fatigue on daily functioning.(82,128) The scale is a 7-point 
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Likert Scale where 1= Strongly Disagree and 7= Strongly Agree. The Score range is 1-7 and a higher 
score indicates more severe fatigue. To determine a score a mean score is calculated. Scores ≥ 4 
indicates severe fatigue.(83) 
 
The Fatigue Scale for Motor and Cognitive Functions (FSMC): 
The FSMC was developed to focus on the two main domains of fatigue: cognitive and physical fatigue. 
In addition, questions are not phrased as such they ask for a reflection over a certain time window (e.g. 
one week).(84) The FSMC also has good reliability, sensitivity and specificity values and the fact that it 
differentiates between physical and cognitive fatigue in MS are important for further understanding of 
the subjectivity of fatigue.(84) The FSMC has 20 items, of which the key cognitive items are 
concentration, decision making/executive functions, learning, occupational demands, stress and 
concentration, heat and thinking, thinking/motivation/drive, verbal fluency, attention/stamina and 
memory. The key physical items are skilfulness, stamina/resting periods, stress and physical power, 
social environment, muscles/strength, physical stamina, drive/motivation, speed reduction, reactivity 
and heat and physical energy.(84) The item responses are rated on a 5-point Likert Scale ranging from, 
“Does not apply at all” to “Applies completely”. The score range is from 20-100 for an overall fatigue 
score. There is a score for cognitive fatigue and physical fatigue. The cut-off values for the sum score 
is ≥ 63 Severe fatigue, ≥ 53 Moderate fatigue and ≥ 43 Mild fatigue; the Cognitive Score is ≥ 34 Severe 
fatigue, ≥ 28 Moderate fatigue and ≥ 22 Mild fatigue; and Physical Score is ≥ 32 Severe fatigue, ≥ 27 
Moderate fatigue and ≥ 22 Mild fatigue.(84) 
 
The Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 
(SF): 
The PROMIS was developed to provide item banks that offer the potential for efficient (minimizes item 
number without compromising reliability), flexible (enables optional use of interchangeable items), and 
precise (has minimal error in estimate) measurement of commonly studied Patient Reported Outcomes 
(PROs).(129) The PROMIS Fatigue SF demonstrated reliability, precision, and construct validity based 
on its correlation with Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale and 
SF-36 Vitality Scale.(129) The PROMIS Fatigue SF is 8 items and has been developed using computer-
adaptive testing.(129) Item responses are rated on a 5-point scale ranging from ‘never’ to ‘always’ and 
are summed and transformed to a T-score metric. Higher scores indicate more severe fatigue. Scores 
2.0 Standard Deviation or worse than the mean = severe symptoms of fatigue which is a ≥65 T-score. 
Moderate fatigue is 55 - 65 T-score, mild fatigue is 50 - 55 T-Score and within normal limits is ≤50 T-
score.(130) It assesses fatigue over the past seven days. PROMIS Fatigue SF scores have good 
precision across different levels of fatigue. More than 95% of the PROMIS samples were measured 
with a reliability greater than 0.9.(81)  
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4.2.2 Data-Analysis 
A Shapiro-Wilk’s test (p>0.05) and visual inspection of their histograms, normal Q-Q plots and box plots 
with skewedness and kurtosis were used to analyse if the data were normally distributed.(91) For data 
that were normally distributed, mean and 95% confidence level (95%CI) are presented. For data that 
were not normally distributed median and interquartile range (IQR) are presented. All analyses were 
conducted using IBM SPSS® version 25 software (IBM SPSS Statistics, IBM Corporation, Armonk, 
New York). A p-value >0.05 was considered statistically significant. To measure agreement between 
the three fatigue questionnaires, we calculated Cohen’s kappa (ĸ) statistics with 95% Confidence 
Interval (CI), interpreting agreement as follows: slight (0–0.20), fair (0.21–0.40), moderate (0.41–0.60), 
substantial (0.61– 0.80), and almost perfect (0.81–1.0). (131) Spearman’s correlation coefficient (r) was 
used to show the strength and the direction of association between the questionnaires. Interpreting the 
strength of the association as follows: -1.0 to -0.5 or 1.0 to 0.5 shows a strong relationship; -0.5 to -0.3 
or 0.3 to 0.5 shows a moderate relationship; -0.3 to -0.1 or 0.1 to 0.3 shows a weak relationship and -
0.1 to 0.1 show no or a very weak relationship.(132)  
 
Subsequently, sensitivity, specificity, positive and negative predictive value for each respective 
questionnaire with the two other questionnaires were calculated (e.g. FSS compared to FSMC sum 
score and PROMIS Fatigue SF). Receiver Operating Characteristics (ROC) curves were used to show 
the graphical representation of sensitivity and specificity for each possible cut-off of the three 
questionnaires and the area under the curve (AUC) helps estimate how high the discriminative power 
of a test is (See Appendix E).(133) AUC and diagnostic accuracy is determined as follows: <0.5 test 
not useful; 0.5-0.6 bad; 0.6-0.7 sufficient; 0.7-0.8 good; 0.8-0.9 very good; 0.9-1.0 excellent.(133) In 
order to discern new cut-off values, that would allow for a 100% certainty that patients classified as 
severe fatigue on questionnaire A would also classify as severely fatigued on questionnaire B, 100% 
specificity was cross-tabulated between all included fatigue questionnaires.(24)  
 
4.3 Results 
There were 122 pwMS (11.6%) who responded to the survey of which 84 completed the complete 
survey. The patient characteristics are summarised in Table 4.1. The majority of the respondents were 
Caucasian (95%), and female (ratio of 6:1) with a mean age of 47 years (95%CI 46 to 49). The 
percentage of pwMS presenting with relapsing remitting MS was 68.1%, 20.7% with secondary 
progressive MS, and 11.2% with primary progressive MS. The median PDDS score was 2 (IQR 1 to 3), 
and subsequently 30.2% of the respondents could be classified as moderately disabled. The median 
years since diagnosis was 7 years (IQR 1-38) and the median years since disease onset was 12 years 
(IQR 1-54). 
 
The results for the three questionnaires are presented in Table 4.2. The FSS median score was 5.17 
(IQR 1-7) with 73.9% of the respondents classified as severely fatigued. The FSMC median scores 
were 39 (IQR 10-50) for the cognitive domain, 41 (IQR 13-50) for the physical domain, and 78.5 (IQR 
23-100) for the summed score. The cut off values for FSMC Cognitive, classified 68.9% of the 
Stellenbosch University https://scholar.sun.ac.za
36 
 
respondents with severe cognitive fatigue, 82.2% with severe physical fatigue and 78.9% with an overall 
severe fatigue. The PROMIS Fatigue SF median score was 59.4 (IQR 33.1 to 78.8). Additionally, based 
on population-norm based cut-off values, 41.1% of the respondents were classified as moderately 
fatigued while 30% of the respondents classified as severely fatigued.  
 
The agreement and the association between the questionnaires are presented in Table 4.3. A significant 
moderate agreement (ĸ =0.563, p = 0.000) and a strong association (r = 0.713, p = 0.000) was found 
between the FSS and FSMC. The agreement between FSMC sum total and PROMIS Fatigue SF was 
slight (ĸ=0.170, p = 0.008) but a strong association (r = 0.624, p = 0.000). FSS and PROMIS fatigue SF 
showed a slight agreement (ĸ=0.194, p = 0.008) but also a strong association (r =0.650, p=0.000). 
Table 4.4 shows the cut offs for both 100% Sensitivity and 100% Specificity. The cut-offs needed for 
100% sensitivity for FSS would be 2.8 and 3.3 to include all pwMS that have severe fatigue on FSMC 
and PROMIS Fatigue SF respectively; for FSMC it would be 43 for both FSS and PROMIS Fatigue SF; 
and for PROMIS Fatigue SF it would be 39.75 and 46.25 T scores for FSMC and FSS respectively. 
Cut-offs at 100% specificity to exclude pwMS that do not have severe fatigue for FSS would be a score 
of 5.8 for FSMC and 6.9 for PROMIS Fatigue SF (98% specificity). For FSMC; a score of 88.5 would 
be required to exclude those without fatigue on the FSS and for PROMIS Fatigue SF, the FSMC score 
would need to be 99 but this would be at 95% specificity. The T scores required on the PROMIS Fatigue 
SF to exclude those with severe fatigue would be 65.85 and 66.95 on the FSMC and FSS respectively.  
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Table 4.1: Demographic Variables and Clinical Characteristics of Persons with Multiple 
Sclerosis in South Africa 
 
95%CI = 95% confidence interval. IQR = Interquartile range. p value = 0.05. RRMS = relapsing-
remitting multiple sclerosis. SPMS = secondary-progressive multiple sclerosis. PPMS = primary-
progressive multiple sclerosis. PDDS = Patient Determined Disease Steps scale. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Demographic 
Characteristics 
Mean 95% Cl N Continuous Health 
Condition Variable 
Median  IQR N 
Age (yrs) 47  46-49 122 Disease diagnosis(yrs) 7 1-38 116 
    Disease onset (yrs) 12 1-54 115 
    PDDS 2 1-3 116 
Categorical 
Variables 
N % N Categorical Variables N % N 
Gender   122 Type of MS   116 
Female 105 86.1  RRMS 79 68.1  
Male 17 13.9  SPMS 24 20.7  
    PPMS 13 11.2  
Ethnicity    122     
White 116 95.1  PDDS   116 
Mixed Ancestry 3 2.5  Mild 55 47.4  
Asian/Indian 2 1.6  Moderate 35 30.2  
Black African 1 0.8  Severe 26 22.4  
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Table 4.2: The Fatigue Severity Scale, the Fatigue Scale for Motor and Physical Functions and 
the PROMIS Fatigue Short Form Questionnaires Median, Interquartile and Categorical Data for 
the Persons with Multiple Sclerosis in South Africa. 
 Median IQR N 
FSS 5.17 1-7 88 
FSMC Cognitive 39.00 10-50 90 
           Motor 41.00 13-50 90 
            Sum Total 78.50 23-100 90 
PROMIS Fatigue SF 59.40 33.1-77.8 90 
Categorical Variables N % N 
FSS   88 
           Score <4 23 26.1  
           Score >4 65 73.9  
FSMC Cognitive   90 
           Within normal limits* 11 12.2  
           Mild 6 6.7  
           Moderate 11 12.2  
           Severe 62 68.9  
FSMC Motor   90 
           Within normal limits* 6 6.7  
          Mild 4 4.4  
           Moderate 6 6.7  
           Severe 74 82.2  
FSMC Sum Total   90 
        Within normal limits* 8 8.9  
          Mild 6 6.7  
          Moderate 5 5.6  
          Severe 71 78.9  
PROMIS Fatigue SF   90 
          Within normal limits 15 16.7  
          Mild 11 12.2  
          Moderate 37 41.1  
         Severe 27 30.0  
IQR = Interquartile range. FSS = Fatigue Severity Scale. FSMC = The Fatigue Scale for Motor and 
Cognitive Functions. PROMIS Fatigue SF = PROMIS Fatigue Short Form. * = FSMC does not have 
“within normal limits” as part of its cut offs so to make it easier for comparison with PROMIS Fatigue 
SF, “within normal limits” were added to scores that fell below the cut off set for mild fatigue. 
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Table 4.3: Cohen’s Kappa for agreement and Spearman’s correlation for associations between 
the Fatigue Severity Scale, the Fatigue Scale for Motor and Physical Functions and the 
PROMIS Fatigue Short Form Questionnaires.  
 
  N ĸ (95% CI) r; p 
FSMC/FSS 88 0.563 (0.341-0.745) 0.713, p=0.000 
FSMC/PROMIS 90 0.170(0.064-0.276) 0.624, p=0.000 
FSS/PROMIS 88 0.194 (0.069-0.319) 0.650, p=0.000 
FSS = Fatigue Severity Scale. FSMC = The Fatigue Scale for Motor and Cognitive Functions. PROMIS = 
PROMIS Fatigue Short Form. ĸ = Cohen’s Kappa. 95% CI = 95% Confidence Interval. r = Spearman’s correlation 
coefficient. Probability (p) = 0.005. 
 
Table 4.4: Optimal cut off values, sensitivity, and specificity, area under the curve, sensitivity 
100% and specificity 100% for the Fatigue Severity Scale, the Fatigue Scale for Motor and 
Physical Functions and the PROMIS Fatigue Short Form Questionnaires 
  N Sensitivity Specificity PPV NPV Score AUC (95%CI) 
Sensitivity 
(100%) 
Specificity 
(100%) 
FSMC/FSS 88 0.86 0.84 0.95 0.62 4.3 0.90 (0.82-0.99) 2.8 5.8 
PROMIS/FSS 88 0.67 0.85 0.67 0.85 5.9 0.82(0.72-0.91) 3.3 6.9* 
FSS/FSMC 88 0.82 0.83 0.93 0.61 72.5 0.87 (0.79-0.96) 43 88.5 
PROMIS/FSMC 90 0.78 0.59 0.45 0.86 77.5 0.73 (0.63-0.84) 43 99** 
FSMC/PROMIS 90 0.82 0.84 0.95 0.55 56.1 0.89(0.80-0.98) 39.75 65.85 
FSS/PROMIS 88 0.85 0.83 0.93 0.66 56.1 0.87(0.78-0.96) 46.25 66.95 
 
PPV = Positive Predictive Value. NPV = Negative Predictive Value. Score = new optimal cut off. AUC = Area 
under the curve. 95% CI = 95% Confidence Interval. FSS = Fatigue Severity Scale. FSMC = the Fatigue Scale 
for Motor and Cognitive Functions. PROMIS = PROMIS Fatigue Short Form. * = Specificity at 98%. ** = 
Specificity at 95%. 
 
4.4 Discussion 
The study of fatigue in patients with Multiple Sclerosis is hampered by the complex, subjective, 
multidimensional character of fatigue. The present study explored the agreement between three fatigue 
measures to classify patients as having severe fatigue based on established cut-off values, and set out 
determined new cut-off values for severe fatigue across these fatigue measures to inform future 
research that aims to study fatigue and the management of fatigue in pwMS.  
 
A significantly moderate agreement was found between the FSS and FSMC, but only slight agreement 
was found between the FSS and FSMC with the PROMIS Fatigue SF. A cut-off value of 5.8 on the FSS 
or cut-off value of 88.5 for the FSMC would allow for the inclusion of patients with severe mental and/or 
physical fatigue (FSMC) and with severe impact on daily functioning (FSS). These cut-off values are 
considerably higher than the original cut-off values of ≥4 for FSS and ≥ 63 for FSMC. However, it would 
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mean that using these higher cut-off values researchers are more likely to include patients with severe 
fatigue in their interventions, and inclusion of patients will be less dependent on the selection of a 
specific questionnaire. The suggestion of using higher cut-off values is in line with previous work. For 
instance, it has been suggested to adjust the FSS cut-off score to at least >5 for studies (or 5.8 
according this the present study) wanting to include severely fatigued pwMS as scores between 4 and 
5 can be considered borderline fatigue.(134,135) 
 
Creating more certainty in terms of the inclusion of fatigue patients is paramount for the research into 
fatigue management of patients with MS. A Cochrane review by Heine et al.(124) found that non-
pharmacological interventions often have not been studied in patients with well-defined levels of fatigue, 
and in addition, fatigue is often not an inclusion criterion or primary outcome. This may lead to an 
underestimation of the true effect on fatigue of those and other fatigue management 
programs.(115,124) Studies performed by Dalgas et al. and Hayes et al. used the FSS (> 4.0) to select 
pwMS that had fatigue a priory. (136,137) Despite heterogeneous findings of exercise therapy for 
fatigue in pwMS, these studies which included fatigued patients specifically, showed significant benefits 
of the studied exercise paradigm on fatigue.(136,137) However, conversely, a study by Aydin et al. 
(FSS) and Skjerbaek et al. (FSMC), showed no significant benefits of exercise therapy on fatigue, 
despite that the baseline fatigue values surpassed the reported cut-off value for the respective 
questionnaire used.(138)(139) The cut-off values derived in the present study, would allow for a more 
stringent classification of severe fatigue as an inclusion criterion, and may facilitate a better estimation 
of the “true” effect of management programs for fatigue in patients with MS. It reduces the bias 
introduced by selecting a specific fatigue questionnaire (e.g. FSS) using original cut-off values, as 
inclusion measure for severely fatigued patients with MS.  
 
While there was a significant and moderate agreement between the FSS and FSMC, the agreement 
between these two fatigue measures and the PROMIS Fatigue SF was unsatisfying. When using the 
PROMIS Fatigue SF, a mere 30% of the participants could be categorised as severely fatigued and 
41.1% as moderately fatigued. In contrast, 73.9% and 78.9% were classified as severely fatigued based 
on the FSS and FSMC respectively. A plausible explanation for the lack of agreement between the 
PROMIS Fatigue SF and the other fatigue measures could be that the questionnaires measure quite 
different domains of fatigue. The PROMIS Fatigue SF cut-off values for this study are similar to the 
suggested cut-off values. This study’s cut-off values are 66.95 and 65.85 and the recommended cut-off 
is ≥65. However, the PROMIS cut-off scores are determined by the American general population 
whereas our cut-offs are determined by pwMS in SA. The PROMIS initiative has developed a fatigue 
short form for pwMS and in validating the content of the questionnaire, they found mean scores on the 
two measures varied by less than one point therefore making the PROMIS Fatigue SF similar to the 
PROMIS Fatigue SF for pwMS making it appropriate for assessing pwMS that have fatigue.(114) 
However, this PROMIS Fatigue SF for pwMS still uses the general population scores to determine the 
cut-offs. There is a need to develop cut-off values based on pwMS as this will help determine 
appropriate categorisations for the different levels of fatigue. 
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There are many different fatigue measures in circulation, and to date there is no true golden standard. 
The present study gives more certainty when using FSS or FSMC for the inclusion of patients with 
severe fatigue and severe impact of fatigue; yet we are unsure how that corresponds with 
questionnaires that allegedly assess other “aspects” of this complex construct. It has been suggested 
that there is a significantly strong association between the FSS and MFIS even though they measure 
different constructs of fatigue.(82,140) Penner et al. eluded to a significant and strong association 
between FSMC and the MFIS and the FSS.(84) This study is a first step in using multiple questionnaires 
to increase certainty of including severely fatigued pwMS and therefore encourage more studies on 
multiple fatigue questionnaires to be utilised when investigating fatigue. This would help to increase the 
standard of the studies done on fatigue on pwMS. The use of PROMIS Fatigue SF is uncertain even 
though the correlation between the PROMIS Fatigue SF and FSS and FSMC was a strong association 
with a slight agreement, there needs to be further investigations into the PROMIS Fatigue SF use. 
These findings may only be true for the South African context but further investigations into the SF and 
its application to other countries is needed. 
 
4.4.1 Limitations 
The limitations of this study include the use of a cross-sectional survey to gather data which relies on 
self-reported data and that there is missing data from some of the fatigue questionnaires which may 
affect the outcomes assessed. The low response rate is a limitation in that it questions whether the data 
gathered from the survey and analysed, is representative of the MS population in South Africa and 
whether it can be applied to the global MS population. The information gathered from the survey is 
important as it shows the need to do further studies into the symptoms and characteristics of pwMS in 
South Africa. Another limitation is that none of the questionnaires for fatigue in this study have been 
extensively validated in a South African context which may not give a true assessment of fatigue 
experienced by South Africans. 
 
4.4.2 Conclusions 
The cut-off values for the FSS and FSMC derived from this study, can be used as more stringent values 
for the inclusion of fatigued patients with MS. It is argued that the use of these higher values may 
increase the precision when studying the effect of fatigue management interventions. Due to the lack 
of agreement with the PROMIS Fatigue SF, further research is needed to clarify the added value of the 
PROMIS Fatigue SF in the study of fatigue in pwMS.  
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CHAPTER 5 
Summary and Conclusion 
 
5.1 Introduction 
The objectives of this thesis was to scope the existing literature on Multiple Sclerosis (MS) originating 
from sub-Saharan Africa, to evaluate the characteristics and key symptoms of persons with MS (pwMS) 
in South Africa (SA) through a cross-sectional study and to investigate the agreement between the 
reported cut-off values for categorising severe fatigue in three fatigue questionnaires and to determine 
new cut-off values to classify a participant as severely fatigued in the three questionnaires. 
 
5.2 Summary: Scoping Review of MS in sub-Saharan Africa 
In Chapter 2, a scoping review of the literature originating in sub-Saharan Africa focusing on MS was 
conducted. A total of 33 studies were included in the review from 1967 to 2018. The review highlighted 
that there is an increase in the reporting of MS amongst Africans across all ethnic groups. However, 
Africa is considered low risk for pwMS because there is very limited research on the epidemiology, 
aetiology and symptoms and experiences of pwMS. Studies conducted on the aetiology of MS in South 
Africa were important studies adding to the global research of MS. Unfortunately, due to low resources 
and MS not being considered a high-risk disease the studies on epidemiology were last conducted in 
2008 in South Africa. The understanding of the symptoms and perceptions of pwMS is also very poorly 
investigated. These findings all indicate large gaps in the research and understanding of MS in sub-
Saharan Africa. 
 
5.3 Summary: Cross-Sectional Study of MS in South Africa 
Chapter 3 investigated the information gathered from a cross-sectional online survey of pwMS in South 
Africa, contacted through the Multiple Sclerosis Society of South Africa. The outcomes were 
consolidated under the International Classification of Functioning (ICF) model, (Health, Body Structure 
and Function, Activity, Participation and Contextual Factors – Personal and Environmental). The 
participants who responded to the survey were 122 out of 1048 (11.6%) pwMS. The cross-sectional 
survey highlighted that pwMS in SA present similarly to pwMS in the Western world in terms of majority 
of the participants were: female (ratio 6:1) even though this ratio is higher than the global statistics for 
female to male ratio, there are still more females than males with MS in SA, Caucasian (95%), disease 
duration of 11 years ± 9 years and majority of the pwMS reported relapsing remitting MS (68.1%). The 
important findings from this cross-sectional survey of pwMS were:  
1) Seventy percent were classified as either overweight or obese according to BMI.  
2) The presence of comorbidities was high, with 39.3% of PwMS reporting three or more 
comorbidities. The most frequent comorbidities reported were depression (36.1%), high blood 
pressure and high cholesterol (20.5%) respectively, migraines (15.6%) and anxiety disorders 
(13.9%).  
3) Detrimental lifestyle behaviour was prevalent with 64% of pwMS being inactive, 66% reported 
having smoked at some time in their lives and 32.3% scored positive for having an alcohol disorder.  
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5.4 Summary: Agreement between three self-report questionnaires to determine severe fatigue 
in Multiple Sclerosis – a cross-sectional study 
Chapter 4 investigated three fatigue questionnaires, the Fatigue Severity Scale (FSS), the Fatigue 
Scale for Motor and Physical outcomes (FSMC) and the PROMIS Fatigue Short Form (SF), and the 
agreement between the reported cut-off values for categorising severe fatigue in the three 
questionnaires and to determine new cut-offs values to classify a participant as severely fatigued across 
all three questionnaires. The data used for this part of the thesis came from the cross-sectional study 
presented in Chapter 3. The main findings were:  
 
1) The FSS and FSMC categorised 73.9% and 78.9% of the participants, respectively as severely 
fatigued. The PROMIS Fatigue SF categorised only 30% as severely fatigued.  
2) A significantly moderate agreement was found between FSS and FSMC, (k = 0.563, p = 0.000), 
and not the PROMIS Fatigue SF.  
3) The new cut-off value for the FSS was 5.8 out of 7 and this value would provide 100% certainty 
that this patient would have qualified as severely fatigued on the FSMC.  
4) The new cut off value for the FSMC was 88.5 out of 100, which would provide 100% certainty that 
this patient would have qualified as severe fatigued on the FSS.  
 
5.5 Summary: Clinical implications 
The main clinical implications of the research presented in this thesis are as follows: 
 It is important to increase awareness of MS in both the public and private sectors of healthcare 
with regards to the signs and symptoms of MS. Creating referral pathways to national or 
international experts in the cases of suspected MS to increase early detection and appropriate 
pharmacological and non-pharmacological management of MS would also be beneficial. This 
would require advocating for better awareness of MS at government level by presenting the 
findings of this study and other studies to the ministry of health to show the need to take more 
interest in this disease. 
 Comorbidities, inactivity, overweight and obesity and smoking are all major concerns for people 
living in sub-Saharan Africa and these issues have a greater impact on pwMS. These issues 
cause delays in diagnosing MS and can be linked to causing MS so education and awareness 
of these concerns need to be made known to pwMS. The prevalence of these risk factors for 
disability and increased disease progression appears higher in a South African context than 
reported for developed countries hence may warrant additional research and awareness. 
Developing consensus guidelines for the diagnosing and treatment of MS in SA and Sub-
Saharan Africa would be beneficial to helping to tackle these issues. Rehabilitation of MS in SA 
is unheard of and developing intervention studies to help assist the management of the 
symptoms of MS amongst pwMS would be most beneficial. 
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 Higher cut-off values, as reported in this thesis for the FSS and FSMC, can be used in clinical 
research in the future, to create a higher level of certainty in studying patients with severe 
fatigue in terms of both severity (FSMC) and impact (FSS). 
 Country specific norms for the PROMIS short forms need to be developed to increase the value 
of the PROMIS initiative. 
 
5.6 Future studies 
 
This thesis has highlighted that there are important gaps in the research on pwMS in sub-Saharan 
Africa, and South Africa specifically. There is no up-to-date research on the epidemiology of MS in sub-
Saharan Africa, despite the increase availability and awareness. A focus shift towards studies 
evaluating the symptom management of pwMS, the impact of the health care systems on their diagnosis 
and treatment options, and validating MS-specific questionnaires that are relevant for the sub-Saharan 
context are justified. Of importance in the South Africa context, is the myriad of comorbidity, and lifestyle 
risk behaviour that may have a negative impact on the disease course and burden. The assessment of 
fatigue, independent of its context, remains complex. Yet, one avenue moving forward, is using more 
stringent inclusion criteria for fatigue severity to obtain better effect estimates of management 
interventions. 
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Sub-Saharan Africa 
1. (Angola[mesh] OR Benin[Mesh] OR Botswana[mesh] OR “Burkina Faso”[Mesh] OR 
Burundi[Mesh] OR “Cape Verde”[Mesh] OR Cameroon[Mesh] OR “Central African 
Republic”[Mesh] OR Chad[Mesh] OR Comoros[Mesh] OR Congo[Mesh] OR Zaire[Mesh] OR 
“Cote d'Ivoire”[Mesh] OR Djibouti[Mesh] OR Eritrea[Mesh] OR Ethiopia[Mesh] OR 
Gabon[Mesh] OR Gambia[Mesh] OR Ghana[Mesh] OR Kenya[Mesh] OR Lesotho[Mesh] OR 
Liberia[Mesh] OR Madagascar[Mesh] OR Malawi[Mesh] or Mali[Mesh] or Mauritius[Mesh] OR 
Mauritania[Mesh] or Mozambique[Mesh] or Namibia[Mesh] OR Niger[Mesh] or Nigeria[Mesh] 
OR “Republic of Guinea”[Mesh] or Rwanda[Mesh] OR Senegal[Mesh] or “Sierra Leone”[Mesh] 
or Somalia[Mesh] or Sudan[Mesh] or “South Africa”[mesh] or Swaziland[Mesh] or 
Tanzania[Mesh] or Togo[Mesh] or Uganda[Mesh] OR Zambia[Mesh] OR Zimbabwe[Mesh]) 
2. Angola[tiab] Or “Benin”[Tiab] Or Botswana[tiab] or "Burkina Faso"[Tiab] OR "Burkina 
Fasso"[Tiab] OR "Upper Volta"[Tiab] OR Burundi[Tiab] OR Urundi[Tiab] OR "Cabo 
Verde"[Tiab] OR "Cape Verde"[Tiab] OR Cameroon[Tiab] OR Cameroons[Tiab] OR 
Cameron[Tiab] OR "Central African Republic"[Tiab] OR Chad[Tiab] OR Comoros[Tiab] OR 
"Comoro Islands"[Tiab] OR Comores[Tiab] OR Mayotte[Tiab] OR Congo[Tiab] OR Zaire[Tiab] 
OR "Cote d'Ivoire"[Tiab] OR "Ivory Coast"[Tiab] OR Djibouti[Tiab] OR "French 
Somaliland"[Tiab] OR Eritrea[Tiab] OR Ethiopia[Tiab] OR Gabon[tiab] OR Gambia[Tiab] OR 
Ghana[Tiab] OR "Gold Coast"[Tiab] OR Kenya[Tiab] OR Lesotho[Tiab] OR Basutoland[Tiab] 
OR Liberia[Tiab] OR Madagascar[Tiab] OR Malawi[Tiab] or Namibia[Tiab] OR Nyasaland[Tiab] 
or Mali[Tiab] or Mauritius[Tiab] OR Mauritania[Tiab] or Mozambique[Tiab] or Niger[Tiab] or 
Nigeria[Tiab] OR “Republic of Guinea”[Tiab] or Rwanda[Tiab] or "Sao Tome"[Tiab] or 
Senegal[Tiab] or "Sierra Leone"[Tiab] or Somalia[Tiab] or “South Africa”[Tiab] or Sudan[Tiab] 
or Swaziland[Tiab] or Tanzania[Tiab] or Togo[Tiab] or "Togolese Republic"[Tiab] or 
Uganda[Tiab] or Yemen[Tiab] OR Zambia[Tiab] OR Zimbabwe[Tiab]) 
3. 2 OR 3 
Multiple sclerosis 
4. ("Multiple Sclerosis"[mh] OR "Encephalomyelitis"[mh] OR "Myelitis"[mh] OR multiple 
scleros*[tiab] OR optic neurit*[tiab] OR acute disseminated encephalomyelit*[tiab] OR 
myelooptic neuropath*[tiab] OR myelo optico neuropath*[tiab] OR myelit*[tiab] OR 
neuromyelitis optica[tiab] OR encephalomyelit*[tiab] OR clinically isolated syndrome*[tiab] OR 
transverse myelit*[tiab] OR devic disease*[tiab] OR devics[tiab] OR demyelinating 
disease*[tiab] OR demyelinating disorder*[tiab] OR adem[tiab]) 
5. 3 AND 4 
6. Limit 5 to humans only
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Please note the following information about your approved research protocol: 
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days of discovery of the incident. You must also report any instances of serious or continuing problems, or non-compliance with the HRECs     
requirements for protecting human research participants. The only exception to this policy is that the death of a research participant must be reported in 
accordance with the Stellenbosch Universtiy Health Research Ethics Committee Standard Operating Procedures   www.sun025.sun.ac.za/portal 
/page/portal/Health_Sciences/English/Centres%20and%20Institutions/Research_Development_Support/Ethics/Application_package All reportable 
events should be submitted to the HREC using the Serious Adverse Event Report   Form. 
 
7. Research Record Keeping. You must keep the following research-related records, at a minimum, in a secure location for a minimum of fifteen years: the 
HREC approved research protocol and all amendments; all informed consent documents; recruiting materials; continuing review reports; adverse or 
unanticipated events; and all correspondence from the HREC 
 
8. Reports to the MCC and Sponsor. When you submit the required annual report to the MCC or you submit required reports to your sponsor, you  
must provide a copy of that report to the HREC. You may submit the report at the time of continuing HREC review. 
 
9. Provision of Emergency Medical Care. When a physician provides emergency medical care to a participant without prior HREC review and approval, 
to the extent permitted by law, such activities will not be recognised as research nor will the data obtained by any such activities should it be used in 
support  of research. 
 
10. Final reports. When you have completed (no further participant enrolment, interactions, interventions or data analysis) or stopped work on your 
research, you must submit a Final Report to the HREC. 
 
11. On-Site Evaluations, MCC Inspections, or Audits. If you are notified that your research will be reviewed or audited by the MCC, the sponsor, 
any other external agency or any internal group, you must inform the HREC immediately of the impending audit/evaluation. 
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Title of Research Project: A cross-sectional survey of comorbidity and risk factors for comorbidity in people with
Multiple Sclerosis living in South Africa
We would like to invite you to take part in a research project which involves the completion of an online
questionnaire. Your participation is entirely voluntary and you are free to decline to participate or to stop completing
the questionnaire at any time, even if you have agreed to take part initially. However, once you have submitted your
completed questionnaire online, you will no longer be able to withdraw your responses as there will be no way of
linking your responses back to you.
This study aims to
- Get a better understanding of people with MS living in South Africa. In particular, how having more than one
medical condition may affect the well-being of people with MS, and which factors might explain which people are
likely or less-likely to develop secondary health conditions next to their Multiple Sclerosis 
- This study is conducted by the Institute of Sports and Exercise Medicine, and division of Physiotherapy, of
Stellenbosch University. 
- All people with MS who are acquainted with "Multiple Sclerosis South Africa" will receive an invitation. 
- Questions will concern your Multiple Sclerosis, secondary health conditions, use of medication, and a variety of
important factors to consider including fatigue, sleep, mood, quality of life, and social participation.
Why are you being asked to participate?
- You are being asked to participate, as you are known within "Multiple Sclerosis South Africa", as an adult (over 18
years old) living with Multiple Sclerosis.
If you agree to participate you will be requested to 
- Complete an online survey which will take approximately one hour to complete. The survey is completely
anonymous unless you decide to disclose your personal information at the end of this survey.
The potential benefits of this research are...
- There are no direct benefits for you if you decide to participate. However, the information we gather due to this
survey, may improve our understanding of people living with MS, in particular those living in South Africa where
multiple sclerosis is relatively rare.
- We will randomly give away five books on health and physical activity for persons with MS. To be eligble to win one
of these books, you will need to disclose your contact details at the end of this survey otherwise we will not know
who to send the book to. This is entirely optional.
Are there any risks involved in your taking part in this research?
- There are no direct risks associated with participating in this study.
- All data gathered from this survey is anonymous, or will be de-identified (in case you decide to disclose your
personal information at the end of the survey). All data gathered will be treated confidentially.
- The online survey is not being run from a "secure" https server of the kind typically used to handle credit card
transactions, so there is a small possibility that responses could be viewed by unauthorized third parties (e.g.,
computer hackers).
- Do not use reply all to the invitation / reminder received from "Multiple Sclerosis South Africa". 
You can email or phone the Principal Investigator of this study, Dr. Martin Heine at 21455899@sun.ac.za  or 076 076
8342 if you have any questions about this study or encounter any problems.
This study has been approved by the Health Research Ethics Committee at Stellenbosch University. The study will be
conducted according to the ethical guidelines and principles of the international Declaration of Helsinki, and the
Department of Health Ethics in Health Research: Principles, Processes and Studies (2015).
You can phone the Health Research Ethics Committee at 021 938 9677/9819 if there still is something that concerns
you about how this study is being conducted, or if you have a complaint.  
A copy of this consent form can be downloaded below.
By clicking SUBMIT you are confirming that you are over 18 years old and have read and understood the above
explanation about the study, and that you agree to participate. You also understand that your participation in this
study is strictly voluntary. 
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In this first section, we will get to know a little bit more about you, your background, and your
living circumstances. Please recall that none of this information can be tracked back to you in
person.
Please state your sex Male
Female
What is your age (years)? __________________________________
(*Years)
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Ethnicity
White Black African Coloured Indian/Asian Other
You
Mother
Father
Mothers Mother
Mothers Father
Fathers Mother
Fathers Father
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 Living and household conditions
Please state your province of residence Northern Cape
Western Cape
Eastern Cape
KwaZulu Natal
Gauteng
Northwest
Free state
Limpopo
Mpumalanga
I'm not a South African resident
Would you consider your home to be in a rural, suburban or urban setting?
Urban area (e.g.larger cities, towns)
Suburban (a residential district located on the outskirts of a city)
Rural area or countryside (a geographic area that is located outside towns and cities).
Whats your marital status?
Single, never married
Married or living with common law partner
Separated
Divorced
Widowed
How many adults (≥ 18 years old), excluding your __________________________________
partner, make up your household? (* Fill in 0 if there are none)
How many children (< 18 years old) make up your __________________________________
household? (* Fill in 0 if there are none)
Could you please provide an estimate of your net (after taxes), yearly, household, income?
(*in ZAR)
R71 479 and above
R28 092 - R71 478
R13 819 - R28 091
R6 486 - R13 818
Up to R6 485
I don't want to disclose this information
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 Education and insurance
What is the highest level of education you have Elementary School
completed? Senior certificate (Grade 12) / High school diploma
Technical college (e.g. business management,
engineering)
Undergraduate (Bachelor)
Graduate (Masters / Honours)
Doctorate degree
Other
If other, please describe: __________________________________
Which option best describes your medical aid? No medical aid
Basic medical aid
Extensive medical aid
Comprehensive medical aid
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Your Multiple Sclerosis
As you might know, not every person with multiple sclerosis (MS) progresses over time in the same way. There are
three basic "types" of MS. Please indicate which description best describes your MS.
Relapsing Remitting MS (RRMS): This is the most common form of MS. About 85% of people with MS are initially
diagnosed with RRMS. People with RRMS have temporary periods called relapses, flare-ups or exacerbations, when
new symptoms appear.
Secondary Progressive MS: SPMS, symptoms worsen more steadily over time, with or without the occurrence of
relapses and remissions. Most people who are diagnosed with RRMS will transition to SPMS at some point.
Primary Progressive MS (PPMS): This type of MS is not very common, occurring in about 10% of people with MS. PPMS
is characterized by slowly worsening symptoms from the beginning, with no relapses or remissions.
Please choose the described disease course that best matches your MS or perhaps your neurologist has told which
type of MS you have.
Relapsing-Remitting MS
Secondary Progressive MS
Primary Progressive MS
Please provide the year in which the first symptoms __________________________________
occurred: (*YYYY)
Please provide the year in which the definite __________________________________
diagnose of MS was made: (*YYYY)
Please read the choices listed below and choose the one that best describes your own situation. This scale focuses
mainly on how well you walk. You might not find a description that reflects your condition exactly, but please mark
the one category that describes your situation the closest.
Normal: I may have some mild symptoms, mostly sensory due to MS but they do not limit my activity. If I do
have an attack, I return to normal when the attack has passed.
Mild Disability: I have some noticeable symptoms from my MS but they are minor and have only a small effect
on my lifestyle.
Moderate Disability: I don't have any limitations in my walking ability. However, I do have significant problems
due to MS that limit daily activities in other ways.
Gait Disability: MS does interfere with my activities, especially my walking. I can work a full day, but athletic
or physically demanding activities are more difficult than they used to be. I usually don't need a cane or
other assistance to walk, but I might need some assistance during an attack.
Early Cane: I use a cane or a single crutch or some other form of support (such as touching a wall or leaning
on someone's arm) for walking all the time or part of the time, especially when walking outside. I think I can
walk 25 feet in 20 seconds without a cane or crutch. I always need some assistance (cane or crutch) if I want
to walk as far as 3 blocks.
Late Cane: To be able to walk 25 feet, I have to have a cane, crutch or someone to hold onto. I can get around
the house or other buildings by holding onto furniture or touching the walls for support. I may use a scooter
or wheelchair if I want to go greater distances.
Bilateral Support: To be able to walk as far as 25 feet I must have 2 canes or crutches or a walker. I may use a
scooter or wheelchair for longer distances.
Wheelchair / Scooter: My main form of mobility is a wheelchair. I may be able to stand and/or take one or two
steps, but I can't walk 25 feet, even with crutches or a walker.
Bedridden: Unable to sit in a wheelchair for more than one hour.
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Use of medication for your MS (disease-modyfing therapy).
Are you currently taking any prescription medication for your multiple sclerosis? Please indicate which:
I'm not taking any disease-modifying medication
Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaseron (interferon beta-1b)
Copaxone (glatiramer acetate)
Extavia (interferon beta-1b)
Gilenya (fingolimod)
Glatopa (glatiramer acetate -- generic equivalent of Copaxone 20mg dose)
Lemtrada (alemtuzumab)
Novantrone (mitoxantrone)
Plegridy (peginterferon beta-1a)
Rebif (interferon beta-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Zinbryta (daclizumab)
Other
You have selected other; please provide the name of the prescription medication you are currently receiving.
 
__________________________________
Stellenbosch University https://scholar.sun.ac.za
09-02-2017 16:59 www.projectredcap.org
Confidential
Page 10 of 48
Medication-use for MS-related symptoms
Are you currently taking medication for any of the following symptoms? (mark all that apply)
Bladder dysfunction
Bowel dysfunction
Depressive symptoms
Dizziness or vertigo
Emotional changes
Fatigue
Pain
Sexual problems
Spasticity
Tremors
Walking (Gait) probems
Please write down the medication(s) you take for bladder dysfunction.
 
__________________________________
Please write down the medication(s) you take for bowel dysfunction.
 
__________________________________
Please write down the medication(s) you take for depressive symptoms.
 
__________________________________
Please write down the medication(s) you take for dizziness or vertigo.
 
__________________________________
Please write down the medication(s) you take for emotional changes.
 
__________________________________
Please write down the medication(s) you take for fatigue.
 
__________________________________
Please write down the medication(s) you take for pain.
 
__________________________________
Please write down the medication(s) you take for spasticity.
 
__________________________________
Please write down the medication(s) you take for tremors (uncontrolled shaking).
 
__________________________________
Please write down the medication(s) you take for walking (gait) problems.
 
__________________________________
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Which of the following supplements do you take? (mark all that apply)
Alpha Lipoic Acid
Asian Ginseng
Bee Venom
Biotin
Bovine Colostrum
Calcium
Cannabidiol
Cranberry
Creatine
Curcumin
Echinacea
Fish Oil
Flaxeed Oil
Gingko Biloba
Glucosamine (Sulfate)
Magnesium
Marijuna / Cannabis
Melatonin
Milk Thistle
Omega-6 Fatty Acids
Phenylalanine
Probiotics
Selenium
St. John's Wort
Threonine
Transfer Factor
Turmeric
Valerian
Vitamin A
Vitamin B6
Vitamin B12
Vitamin C
Vitamin D
Vitamin E
Zinc
Other
I'm not taking any supplements
If other, please describe
 
__________________________________
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The next section is about other medical conditions you might have, next to the MS. In the
context of this study, this section is very important. Hence please take a moment to go
through each of the options and mark all that apply. 
Has a doctor ever told you that you have any of the following conditions? (Mark all that apply)
None
High cholesterol (hyperlipidemia)
High blood pressure (hypertension)
Heart trouble (such as angina, congestive heart failure, or coronary artery disease)
Disease of arteries in the legs (peripheral vascular disease)
Lung trouble (asthma, emphysema, chronic bronchitis, COPD)
Diabetes mellitus
Cancer of the breast
Cancer of the colon (large bowel)
Cancer of the rectum
Cancer of the lung
Skin cancer
Other cancers
Uveitis (inflammation of the eye)
Glaucoma
Cataracts
Migraine
Thyroid disease (such as Graves' disease, Hashimoto's thyroiditis; not thyroid cancer)
Vitamin B 12 deficiency (pernicious anemia)
Lupus (systemic lupus erythematosus, SLE)
Sjögren's syndrome
Inflammatory bowel disease (Crohn's disease, ulcerative colitis)
Rheumatoid arthritis
Degenerative arthritis (osteoarthritis)
Osteoporosis (bone disease causing thin bones leading to fractures of the hip, wrist, and spine)
Hip replacement(s)
Knee replacement(s)
Fibromyalgia
Anemia or other blood disease
Kidney disease
Open sore or ulcer in the lining of the stomach, esophagus, duodenum (peptic ulcer disease)
Liver problems (such as cirrhosis)
Irritable bowel syndrome
Epilepsy (seizure disorder)
Depression
Anxiety disorder
Bipolar disorder (manic depression)
Schizophrenia
HIV / AIDS
Tuberculosis
Please provide the year of diagnosis for "high __________________________________
cholesterol (hyperlipidemia)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "high blood __________________________________
pressure (hypertension)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
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Please provide the year of diagnosis for "Heart __________________________________
trouble (such as angina, congestive heart failure, (*YYYY)
or coronary artery disease)"
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Disease of __________________________________
arteries in the legs (peripheral vascular disease)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Lung __________________________________
trouble (asthma, emphysema, chronic bronchitis, or (*YYYY)
COPD)"
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Diabetes __________________________________
mellitus" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "cancer of __________________________________
the breast" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "cancer of __________________________________
the colon (large bowel)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "cancer of __________________________________
the rectum" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "cancer of __________________________________
the lung" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "skin __________________________________
cancer" (*YYYY)
Please describe the type of skin cancer: __________________________________
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "other type __________________________________
of cancer" (*YYYY)
Please describe the other type of cancer: __________________________________
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Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Uveitis __________________________________
(inflammation of the eye)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Glaucoma" __________________________________
(*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Cataracts" __________________________________
(*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Migraine" __________________________________
(*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Thyroid __________________________________
disease (such as Graves' disease, Hashimoto's (*YYYY)
thyroiditis; not thyroid cancer)"
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Vitamin B __________________________________
12 deficiency (pernicious anemia)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Lupus __________________________________
(systemic lupus erythematosus, SLE)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Sjögren's __________________________________
syndrome" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for __________________________________
"Inflammatory bowel disease (Crohn's disease, (*YYYY)
ulcerative colitis)"
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Rheumatoid __________________________________
arthritis" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
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Please provide the year of diagnosis for __________________________________
"Degenerative arthritis (osteoarthritis)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for __________________________________
"Osteoporosis (bone disease causing thin bones (*YYYY)
-leading to fractures of the hip, wrist, and spine)"
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Hip __________________________________
replacement(s)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Knee __________________________________
replacement(s)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for __________________________________
"Fibromyalgia" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Anemia or __________________________________
other blood disease" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Kidney __________________________________
disease" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Open sore __________________________________
or ulcer in the lining of the stomach, esophagus, (*YYYY)
duodenum (peptic ulcer disease)"
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Liver __________________________________
problems (such as cirrhosis)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Irritable __________________________________
bowel syndrome" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Epilepsy __________________________________
(seizure disorder)" (*YYYY)
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Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Depression" __________________________________
(*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Anxiety __________________________________
disorder" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "Bipolar __________________________________
disorder (manic depression)" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for __________________________________
"Schizophrenia" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for "HIV / AIDS" __________________________________
(*YYYY)
Are you currently receiving treatment for this Yes
condition? No
Please provide the year of diagnosis for __________________________________
"Tuberculosis" (*YYYY)
Are you currently receiving treatment for this Yes
condition? No
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Trouble with the locomotive organs.
In the below picture you can see the approximate position of the parts of the body referred to in the next set of
questions. Limits are not sharply defined and parts may overlap. You should decide for yourself in which part you had
trouble (if any).
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Have you add any time during the last 12 months had trouble (pain, ache, discomfort) in: 
No Yes
Neck
Shoulders
Elbows
Wrists/hands
Upper back
Lower back (small of the back)
One of both hips/thighs
One or both knees
One of both ankles/feet
Regarding your neck trouble; have you had any time Yes
during the last 12 months been prevented from doing No
your normal work (at home or away from home) because
of your neck trouble?
Have you had any neck trouble at any time during the Yes
past 7 days? No
Do you consider your neck trouble a directly related Yes
to your MS? (e.g. neuropathic pain, or muscle No
stiffness, spasms)
Do you have shoulder trouble in: the left shoulder
the right shoulder
both shoulders
Regarding your shoulders; have you had any time Yes
during the last 12 months been prevented from doing No
your normal work (at home or away from home) because
of your shoulder trouble?
Have you had any shoulder trouble at any time during Yes
the past 7 days? No
Do you consider your shoulder trouble directly Yes
related to your MS? (e.g. neuropathic pain, or No
muscle stiffness, spasms)
Do you have elbow trouble in: the left elbow
the right elbow
both elbows
Regarding your elbows; have you had any time during Yes
the last 12 months been prevented from doing your No
normal work (at home or away from home) because of
your elbow trouble?
Have you had any elbow trouble at any time during the Yes
past 7 days? No
Do you consider your elbow trouble directly related Yes
to your MS? (e.g. neuropathic pain, or muscle No
stiffness, spasms)
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Do you have hand/wrist trouble in: the left hand/wrist
the right hand/wrist
both hands/wrists
Regarding your hands/wrists; have you had any time Yes
during the last 12 months been prevented from doing No
your normal work (at home or away from home) because
of your hand/wrist trouble?
Have you had any hand/wrist trouble at any time Yes
during the past 7 days? No
Do you consider your hand/wrists trouble directly Yes
related to your MS? (e.g. neuropathic pain, or No
muscle stiffness, spasms)
Regarding your upper back; have you had any time Yes
during the last 12 months been prevented from doing No
your normal work (at home or away from home) because
of your upper back trouble?
Have you had any upper back trouble at any time Yes
during the past 7 days? No
Do you consider your upper back trouble directly Yes
related to your MS? (e.g. neuropathic pain, or No
muscle stiffness, spasms)
Regarding your lower back; have you had any time Yes
during the last 12 months been prevented from doing No
your normal work (at home or away from home) because
of your lower back trouble?
Have you had any lower back trouble at any time Yes
during the past 7 days? No
Do you consider your lower back trouble directly Yes
related to your MS? (e.g. neuropathic pain, or No
muscle stiffness, spasms)
Regarding your hips/thighs; have you had any time Yes
during the last 12 months been prevented from doing No
your normal work (at home or away from home) because
of your hips/thighs trouble?
Have you had any hips/thighs trouble at any time Yes
during the past 7 days? No
Do you consider your hip/thigh trouble directly Yes
related to your MS? (e.g. neuropathic pain, or No
muscle stiffness, spasms)
Regarding your knees; have you had any time during Yes
the last 12 months been prevented from doing your No
normal work (at home or away from home) because of
your knees trouble?
Have you had any knees trouble at any time during the Yes
past 7 days? No
Do you consider your knee trouble directly related to Yes
your MS? (e.g. neuropathic pain, or muscle No
stiffness, spasms)
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Regarding your ankles/feet; have you had any time Yes
during the last 12 months been prevented from doing No
your normal work (at home or away from home) because
of your ankles/feet trouble?
Have you had any ankles/feet trouble at any time Yes
during the past 7 days? No
Do you consider your ankle/feet trouble directly Yes
related to your MS? (e.g. neuropathic pain, or No
muscle stiffness, spasms)
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Body composition
What is your current body weight in kilograms? __________________________________
What is your current height in centimeters? __________________________________
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Smoking
When was the last time you smoked a cigarette even a Less than one day ago
single puff? 1-7 days ago
8-30 days ago
31-90 days ago
90-180 days ago
180-365 days ago
More than 1 year ago
I have not smoked at least 100 cigarettes in my
lifetime.
On average in the past 7 days, how many cigarettes Nothing in the past 7 days
have you smoked per day? Less than 1 cigarette per day on average in the
past 7 days
1-5 cigarettes per day in the past 7 days
6-10 cigarettes per day in the past 7 days
11-20 cigarettes per day in the past 7 days
21-40 cigarettes per day in the past 7 days
More than 40 cigarettes per day in the past 7 days
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Alcohol consumption
How often do you have a drink containing alcohol?
Never
Monthly or less
2-4 times a month
2-3 times a week
4 or more times a week
How many standard drinks containing alcohol do you have on a typical day?
1 or 2
3 or 4
5 or 6
7 to 9
10 or more
How often do you have six or more drinks on one occasion?
Never
Less than monthly
Monthly
Weekly
Daily or almost daily
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Sports and Exercise participation
During the last 12 months did you participate in any Yes
physical activities for exercise, recreation or No
sport? Don't know / unsure
How many different physical activities for exercise, 1
recreation or sport did you participate in? 2
3,
More than 3
Can you shortly describe the most frequent physical __________________________________
activity for exercise, recreation or sport you
participated in? For example soccer, squash, or
brisk walking.
On average, how often did you participate in this Less than once a month
physical activity for exercise, recreation or sport? One to three times a month
Once a week
Twice a week
More than twice a week
Would you consider this particular physical activity Low intensity
for exercise, recreation or sport: Moderate intensity
High intensity
Can you shortly describe the second most frequent __________________________________
physical activity for exercise, recreation or sport
you participated in? For example soccer, squash, or
brisk walking.
On average, how often did you participate in this Less than once a month
physical activity for exercise, recreation or sport? One to three times a month
Once a week
Twice a week
More than twice a week
Would you consider this particular physical activity Low intensity
for exercise, recreation or sport: Moderate intensity
High intensity
Can you shortly describe the third most frequent __________________________________
physical activity for exercise, recreation or sport
you participated in? For example soccer, squash, or
brisk walking.
On average, how often did you participate in this Less than once a month
physical activity for exercise, recreation or sport? One to three times a month
Once a week
Twice a week
More than twice a week
Would you consider this particular physical activity Low intensity
for exercise, recreation or sport: Moderate intensity
High intensity
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Dietary habits
How would you rate your personal dietary habits
and/or food intake? Unhealthy Healthy
(Place a mark on the scale above)           
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The following questionnaire is about problems in everyday life which are directly associated
with an extreme form of tiredness (fatigue). This extreme form of tiredness refers to an
overwhelming state of lethargy, exhaustion and lack of energy which comes on abruptly and is
unrelated to any obvious external causes. It does not mean the sort of isolated episodes which
everyone might experience in the course of the day, after exertion, or after a sleepless night.
Please read each statement carefully. Then decide to what extent each statement applies to
you and your everyday life. Please try not to base your answers on the way you are feeling at
the moment; instead try to give us a picture of the way you feel in normal day-to-day life.
Please select the appropriate circle.
Does not apply
at all
Does not apply
much
Slightly applies Applies a lot Applies
completely
177)When I concentrate for a long
time, I get exhausted sooner
than other people of my age
178)When I am experiencing
episodes of exhaustion, my
movements become noticeably
clumsier and less coordinated
179) Because of my episodes of
exhaustion, I now need more
frequent and/or longer rests
during physical activity than I
used to
180) When I am experiencing
episodes of exhaustion, I am
incapable of making decisions
181) When faced with stressful
situations, I now find that I get
physically exhausted quicker
than I used to
182) Because of my episodes of
exhaustion, I now have
considerably less social contact
than I used to
183) Because of my episodes of
exhaustion, I now find it more
difficult to learn new things than
I used to
184) The demands of my work
exhaust me mentally more
quickly than they used to
185)
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I feel the episodes of exhaustion
particularly strongly in my
muscles
186) I no longer have the stamina for
long periods of physical activity
that I used to have
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Does not apply
at all
Does not apply
much
Slightly applies Applies a lot Applies
completely
187) My powers of concentration
decrease consi- derably when
I'm under stress
188) When I am experiencing
episodes of exhaustion, I am less
motivated than others to start
activities that involve physical
effort
189) My thinking gets increasingly
slow when it is hot
190) When I am experiencing an
episode of exhaustion, my
movements become noticeably
slower
191) Because of my episodes of
exhaustion, I now feel less like
doing things which require
concentration
192)When an episode of exhaustion
comes on, I am simply no longer
able to react quickly
193) When I am experiencing
episodes of exhaustion, certain
words simply escape me
194)When I am experiencing
episodes of exhaustion, I lose
concentration considerably
quicker than I used to
195) When it is hot, my main feeling
is one of extreme physical
weakness and lack of energy
196) During episodes of exhaustion, I
am noticeably more forgetful
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197) In the past 7 days, Never
My thinking has been slow Rarely (Once)
Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
198) In the past 7 days, Never
It has seemed like my brain was not working as well Rarely (Once)
as usual Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
199) In the past 7 days, Never
I have had to work harder than usual to keep track of Rarely (Once)
what I was doing Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
200) In the past 7 days, Never
I have had trouble shifting back and forth between Rarely (Once)
different activities that require thinking Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
201) In the past 7 days, Never
I have had trouble concentrating Rarely (Once)
Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
202) In the past 7 days, Never
I have had to work really hard to pay attention or I Rarely (Once)
would make a mistake Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
203) In the past 7 days, Never
I have had trouble forming thoughts Rarely (Once)
Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
204) In the past 7 days, Never
I have had trouble adding or subtracting numbers in Rarely (Once)
my head Sometimes (Two or three times)
Often (About once a day)
Very often (Several times a day)
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You're about halfway now. Please feel free to take a break and continue later. However, we
would really appreciate it if you could complete the questionnaire on the same day you
started.
Are you able to walk, even if it is just a little Yes
bit? No
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In the past two weeks, how much has your MS:
Not at all A little Moderately Quit a lot Extremely
Limited your ability to walk?
Limited your ability to run?
Limited your ability to climb up
and down stairs?
Made standing when doing
things more difficult?
Limited your balance when
standing or walking?
Limited how far you are able to
walk?
Increased the effort needed for
you to walk?
Made it necessary for you to use
support when walking indoors
(eg holding on to furniture, using
a stick, etc.)?
Made it necessary for you to use
support when walking outdoors
(eg using a stick, a frame, etc.)?
Slowed down your walking?
Affected how smoothly you
walk?Made you concentrate on your
walking?
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We are interested in finding out about the kinds of physical activities that people do as part of
their everyday lives. Your answers will help us to understand how active we are compared
with people in other countries. The questions are about the time you spent being physically
active in the last 7 days. They include questions about activities you do at work, as part of
your house and yard work, to get from place to place, and in your spare time for recreation,
exercise or sport. Please answer each question even if you do not consider yourself to be an
active person. In answering the following questions, vigorous physical activities refer to
activities that take hard physical effort and make you breathe much harder than normal.
moderate activities refer to activities that take moderate physical effort and make you
breathe somewhat harder than normal.
1a. During the last 7 days, on how many days did you 1 day per week
do vigorous physical activities like heavy lifting, 2 days per week
digging, aerobics, or fast bicycling? 3 days per week
4 days per week
Think about only those physical activities that you 5 days per week
did for at least 10 minutes at a time. 6 days per week
7 days per week
none
1b.	How much time in total did you usually spend on one of those days doing vigorous physical activities?
hours __________________________________
minutes __________________________________
2a. Again, think only about those physical activities 1 day per week
that you did for at least 10 minutes at a time. 2 days per week
During the last 7 days, on how many days did you do 3 days per week
moderate physical activities like carrying light 4 days per week
loads, bicycling at a regular pace, or doubles 5 days per week
tennis? Do not include walking. 6 days per week
7 days per week
none
2b.	How much time in total did you usually spend on one of those days doing moderate physical activities?
hours __________________________________
minutes __________________________________
3a.	During the last 7 days, on how many days did you 1 day per week
walk for at least 10 minutes at a time? This 2 days per week
includes walking at work and at home, walking to 3 days per week
travel from place to place, and any other walking 4 days per week
that you did solely for recreation, sport, exercise 5 days per week
or leisure. 6 days per week
7 days per week
none
3b.	How much time in total did you usually spend walking on one of those days?
hours __________________________________
minutes __________________________________
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The last question is about the time you spent sitting on weekdays while at work, at home, while doing course work
and during leisure time.  This includes time spent sitting at a desk, visiting friends, reading traveling on a bus or
sitting or lying down to watch television.
4. During the last 7 days, how much time in total did you usually spend sitting on a week day?
hours __________________________________
minutes __________________________________
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229) During the past 7 days: Not at all
I feel fatigued A little bit
Somewhat
Quite a bit
Very much
230) In the past 7 days Not at all
How fatigued were you on average? A little bit
Somewhat
Quite a bit
Very much
231) In the past 7 days Not at all
How run-down did you feel on average? A little bit
Somewhat
Quite a bit
Very much
232) During the past 7 days: Not at all
I have trouble starting things because I am tired A little bit
Somewhat
Quite a bit
Very much
233) In the past 7 days Not at all
How much were you bothered by your fatigue on A little bit
average? Somewhat
Quite a bit
Very much
234) In the past 7 days Not at all
To what degree did your fatigue interfere with your A little bit
physical functioning? Somewhat
Quite a bit
Very much
235) In the past 7 days Never
How often did you have to push yourself to get things Rarely
done because of your fatigue? Sometimes
Often
Always
236) In the past 7 days Never
How often did you have trouble finishing things Rarely
because of your fatigue? Sometimes
Often
Always
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237) Mobility
I have no problems walking about
I have slight problems walking about
I have moderate problems walking about
I have severe problems walking about
I am unable to walk about
238) Self-care
I have no problems washing or dressing myself
I have slight problems washing or dressing myself
I have moderate problems washing or dressing myself
I have severe problems washing or dressing myself
I am unable to wash or dress myself
239) Usual activities (e.g. work, study, housework)
I have no problems doing my usual activities
I have slight problems doing my usual activities
I have moderate problems doing my usual activities
I have severe problems doing my usual activities
I am unable to do my usual activities
240) Pain / Discomfort
I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
241) Anxiety / Depression
I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am severely anxious or depressed
I am extremely anxious or depressed
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GENERAL HEALTH
242) 1. We would like to know how your health is today
2. This scale is marked from 0 - 100
3. 100 means the best health you can imagine, 0 means the worst health you can imagine
4. Move the slider to indicate how your health is today
The worst health The best health
you can imagine you can imagine
                                                             (Place a mark on the scale above)
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This questionnaire helps to know how you are feeling. Read every sentence. Select the button
of the answer that best describes how you have been feeling during the LAST WEEK. You do
not have to think too much to answer. In this questionnaire, spontaneous answers are more
important.
243) I feel tense or 'wound up' Most of the time
A lot of the time
From time to time (occasionally)
Not at all
244) I still enjoy the things I used to enjoy Definitely as much
Not quite as much
Only a little
Hardly at all
245) I get a sort of frightened feeling as if something Very definitely and quite badly
awful is about to happen Yes, but not too badly
A little, but it doesn't worry me
Not at all
246) I can laugh and see the funny side of things As much as I always could
Not quite so much now
Definitely not so much now
Not at all
247) Worrying thoughts go through my mind A great deal of the time
A lot of the time
From time to time, but not often
Only occasionally
248) I feel cheerful Not at all
Not often
Sometimes
Most of the time
249) I can sit at ease and feel relaxed Definitely
Usually
Not often
Not at all
250) I feel as if I am slowed down Nearly all the time
Very often
Sometimes
Not at all
251) I get a sort of frightened feeling like "butterflies" Not at all
in the stomach Occasionally
Quite often
Very often
252) I have lost interest in my appearance Definitely
I don't take as much care as I should
I may not take quite as much care
I take just as much care
253) I feel restless as I have to be on the move Very much indeed
Quite a lot
Not very much
Not at all
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254) I look forward with enjoyment to things As much as I ever did
Rather less than I used to
Definitely less than I used to
Hardly at all
255) I get sudden feelings of panic Very often indeed
Quite often
Not very often
Not at all
256) I can enjoy a good book or radio/TV program Often
Sometimes
Not often
Very seldom
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257) I have trouble doing all of my regular leisure Never
activities with others Rarely
Sometimes
Usually
Always
258) I have trouble doing all of the family activities Never
that I want to do Rarely
Sometimes
Usually
Always
259) I have trouble doing all of my usual work (include Never
work at home) Rarely
Sometimes
Usually
Always
260) I have trouble doing all of the activities with Never
friends that I want to do Rarely
Sometimes
Usually
Always
261) I have to limit the things I do for fun with others Never
Rarely
Sometimes
Usually
Always
262) I have to limit my regular activities with friends Never
Rarely
Sometimes
Usually
Always
263) I have to limit my regular family activities Never
Rarely
Sometimes
Usually
Always
264) I have trouble doing all of the work that is really Never
important to me (include work at home) Rarely
Sometimes
Usually
Always
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The next 9 question are about your fatigue over the past week. Please answer on a score
between 1 (Disagree) to 7 (Agree)
Over the past week, I found that
1
(Disagree)
2 3 4 5 6 7 (Agree)
265) My motivation is lower when I
am fatigued
266) Exercise brings on my fatigue
267) I am easily fatigued
268) Fatigue interferes with my
physical functioning
269) Fatigue causes frequent
problems for me
270) My fatigue prevents sustained
physical functioning
271) Fatigue interferes with carrying
out certain duties and
responsibilities
272) Fatigue is among the three most
disabling symptoms
273) Fatigue interferes with my work,
family, or social life
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In the past 7 days Not at all
I was satisfied with my sleep. A little bit
Somewhat
Quite a bit
Very much
In the past 7 days Not at all
My sleep was refreshing. A little bit
Somewhat
Quite a bit
Very much
In the past 7 days Not at all
I had a problem with my sleep. A little bit
Somewhat
Quite a bit
Very much
In the past 7 days Not at all
I had difficulty falling asleep. A little bit
Somewhat
Quite a bit
Very much
In the past 7 days Not at all
My sleep was restless. A little bit
Somewhat
Quite a bit
Very much
In the past 7 days Not at all
I tried hard to get to sleep. A little bit
Somewhat
Quite a bit
Very much
In the past 7 days Not at all
I worried about not being able to fall asleep. A little bit
Somewhat
Quite a bit
Very much
In the past 7 days Very poor
My sleep quality was... Poor
Fair
Good
Very good
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That's it! You are all done!
Thank you for your time and effort in completing this survey.
Please mark that apply.
(If you agree to either one of the two options above, you will be asked to provide your email-adress so we can
contact you. However, please note when processing this survey, this information is disregarded and your results
remain completely anonymous.)
Would it be alright if we contact you again in one years time to repeat this survey?
Would you like to be eligible for winning one of five copies of "Everyday Health and Fitness with Multiple
Sclerosis, by David Lyons and Jacob Sloane", published in February 2017
Email:
 
__________________________________
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Comorbidity (122 respondents) N (%) 
Anemia or other blood disease 11 (9) 
Anxiety disorder 17(13.9) 
Bipolar disorder (manic depression) 3 (2.5) 
Cancer of the breast 1 (0.8) 
Cancer of the colon (large bowel) 1 (0.8) 
Cancer of the lung 1 (0.8) 
Cancer of the rectum 1 (0.8) 
Cataracts 7 (5.7) 
Degenerative arthritis (osteoarthritis) 6 (4.9) 
Depression 44 (36.1) 
Diabetes Mellitus 6 (4.9) 
Disease of arteries in the legs (peripheral vascular disease) 3 (2.5) 
Epilepsy (seizure disorder) 8 (6.6) 
Fibromyalgia 5 (4.1) 
Glaucoma 3 (2.5) 
Heart trouble (such as angina, congestive heart failure, or coronary artery disease) 5 (4.1) 
High blood pressure (hypertension) 25 (20.5) 
High cholesterol (hyperlipidaemia) 25 (20.5) 
Hip replacement(s) 1 (0.8) 
HIV / AIDS 0  
Inflammatory bowel disease (Crohn's disease, ulcerative colitis) 2 (1.6) 
Irritable bowel syndrome 13 (10.7) 
Kidney disease 3 (2.5) 
Knee replacement(s) 3 (2.5) 
Liver problems (such as cirrhosis) 5 (4.1) 
Lung trouble (asthma, emphysema, chronic bronchitis, COPD) 16 (13.1) 
Lupus (systemic lupus erythematosus, SLE) 2 (1.6) 
Migraine 19 (15.6) 
Open sore or ulcer in the lining of the stomach, oesophagus, duodenum (peptic ulcer 
disease) 
6 (4.9) 
Osteoporosis (bone disease causing thin bones leading to fractures of the hip, wrist, and 
spine) 
3 (2.5) 
Other cancers 2 (1.6) 
Rheumatoid arthritis 2 (1.6) 
Schizophrenia 0 
Sjögren's syndrome 0 
Skin cancer 4 (3.3) 
Thyroid disease (such as Graves' disease, Hashimoto's thyroiditis; not thyroid cancer) 11 (9.0) 
Tuberculosis 0 
Uveitis (inflammation of the eye) 1 (0.8) 
Vitamin B 12 deficiency (pernicious anaemia) 7 (5.7) 
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ROC curves Fatigue Severity Scale (FSS), the Fatigue Scale for Motor and Physical 
Functions (FSMC) and the PROMIS Fatigue Short Form Questionnaires 
                                                             
1.FSS/PROMIS                                                        2. FSS/FSMC 
                           
3.PROMIS/FSS                   4. PROMIS/FSMC 
                              
5.FSMC/FSS                                                              6. FSMC/PROMIS 
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Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for 
Scoping Reviews (PRISMA-ScR) Checklist 
SECTION ITEM PRISMA-ScR CHECKLIST ITEM REPORTED ON PAGE # 
TITLE 
Title 1 Identify the report as a scoping review. 4 
ABSTRACT 
Structured 
summary 2 
Provide a structured summary that includes (as 
applicable): background, objectives, eligibility 
criteria, sources of evidence, charting methods, 
results, and conclusions that relate to the review 
questions and objectives. 
4 
INTRODUCTION 
Rationale 3 
Describe the rationale for the review in the context 
of what is already known. Explain why the review 
questions/objectives lend themselves to a scoping 
review approach. 
5 
Objectives 4 
Provide an explicit statement of the questions and 
objectives being addressed with reference to their 
key elements (e.g., population or participants, 
concepts, and context) or other relevant key 
elements used to conceptualize the review 
questions and/or objectives. 
5 
METHODS 
Protocol and 
registration 5 
Indicate whether a review protocol exists; state if 
and where it can be accessed (e.g., a Web 
address); and if available, provide registration 
information, including the registration number. 
5 
Eligibility criteria 6 
Specify characteristics of the sources of evidence 
used as eligibility criteria (e.g., years considered, 
language, and publication status), and provide a 
rationale. 
5-6 
Information 
sources* 7 
Describe all information sources in the search (e.g., 
databases with dates of coverage and contact with 
authors to identify additional sources), as well as 
the date the most recent search was executed. 
5 
Search 8 
Present the full electronic search strategy for at 
least 1 database, including any limits used, such 
that it could be repeated. 
Appendix A 
Selection of 
sources of 
evidence† 
9 
State the process for selecting sources of evidence 
(i.e., screening and eligibility) included in the 
scoping review. 
6 
Data charting 
process‡ 10 
Describe the methods of charting data from the 
included sources of evidence (e.g., calibrated forms 
or forms that have been tested by the team before 
their use, and whether data charting was done 
independently or in duplicate) and any processes 
for obtaining and confirming data from 
investigators. 
6 
Data items 11 
List and define all variables for which data were 
sought and any assumptions and simplifications 
made. 
6 
Critical appraisal 
of individual 
sources of 
evidence§ 
12 
If done, provide a rationale for conducting a critical 
appraisal of included sources of evidence; describe 
the methods used and how this information was 
used in any data synthesis (if appropriate). 
Click here to 
enter text. 
Synthesis of 
results 13 
Describe the methods of handling and summarizing 
the data that were charted. 6 
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SECTION ITEM PRISMA-ScR CHECKLIST ITEM REPORTED ON PAGE # 
RESULTS 
Selection of 
sources of 
evidence 
14 
Give numbers of sources of evidence screened, 
assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally 
using a flow diagram. 
Fig 2.1 p13 
Characteristics of 
sources of 
evidence 
15 
For each source of evidence, present 
characteristics for which data were charted and 
provide the citations. 
Table 2.1 p8 
Critical appraisal 
within sources of 
evidence 
16 If done, present data on critical appraisal of included sources of evidence (see item 12). 
Click here to 
enter text. 
Results of 
individual sources 
of evidence 
17 
For each included source of evidence, present the 
relevant data that were charted that relate to the 
review questions and objectives. 
13 
Synthesis of 
results 18 
Summarize and/or present the charting results as 
they relate to the review questions and objectives. 13 
DISCUSSION 
Summary of 
evidence 19 
Summarize the main results (including an overview 
of concepts, themes, and types of evidence 
available), link to the review questions and 
objectives, and consider the relevance to key 
groups. 
14 
Limitations 20 Discuss the limitations of the scoping review process. 15 
Conclusions 21 
Provide a general interpretation of the results with 
respect to the review questions and objectives, as 
well as potential implications and/or next steps. 
15 
FUNDING 
Funding 22 
Describe sources of funding for the included 
sources of evidence, as well as sources of funding 
for the scoping review. Describe the role of the 
funders of the scoping review. 
NA 
JBI = Joanna Briggs Institute; PRISMA-ScR = Preferred Reporting Items for Systematic reviews and Meta-
Analyses extension for Scoping Reviews. 
* Where sources of evidence (see second footnote) are compiled from, such as bibliographic databases, social 
media platforms, and Web sites. 
† A more inclusive/heterogeneous term used to account for the different types of evidence or data sources (e.g., 
quantitative and/or qualitative research, expert opinion, and policy documents) that may be eligible in a scoping 
review as opposed to only studies. This is not to be confused with information sources (see first footnote). 
‡ The frameworks by Arksey and O’Malley (6) and Levac and colleagues (7) and the JBI guidance (4, 5) refer to 
the process of data extraction in a scoping review as data charting. 
§ The process of systematically examining research evidence to assess its validity, results, and relevance before 
using it to inform a decision. This term is used for items 12 and 19 instead of "risk of bias" (which is more 
applicable to systematic reviews of interventions) to include and acknowledge the various sources of evidence 
that may be used in a scoping review (e.g., quantitative and/or qualitative research, expert opinion, and policy 
document). 
 
 
From: Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist 
and Explanation. Ann Intern Med. ;169:467–473. doi: 10.7326/M18-0850 
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STROBE Statement—checklist of items that should be included in reports of observational studies 
 
  
Item 
No Recommendation 
Chapter 
3     
Page  
No 
Chapter 
4     
Page  
No 
Title and abstract 1 (a) Indicate the study’s design with a commonly used 
term in the title or the abstract 
16 35 
(b) Provide in the abstract an informative and 
balanced summary of what was done and what was 
found 
16 35 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for 
the investigation being reported 
17 36 
Objectives 3 State specific objectives, including any prespecified 
hypotheses 
17 36 
Methods  
Study design 4 Present key elements of study design early in the 
paper 
17 37 
Setting 5 Describe the setting, locations, and relevant dates, 
including periods of recruitment, exposure, follow-
up, and data collection 
17 37 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the 
sources and methods of selection of participants. 
Describe methods of follow-up 
Case-control study—Give the eligibility criteria, and 
the sources and methods of case ascertainment and 
control selection. Give the rationale for the choice of 
cases and controls 
Cross-sectional study—Give the eligibility criteria, 
and the sources and methods of selection of 
participants 
 
 
 
 
 
 
 
 
17 
   
 
 
 
 
 
 
 
37 
(b) Cohort study—For matched studies, give 
matching criteria and number of exposed and 
unexposed 
Case-control study—For matched studies, give 
matching criteria and the number of controls per 
case 
  
Variables 7 Clearly define all outcomes, exposures, predictors, 
potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
18-20 37-38 
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Data sources/ 
measurement 
8*  For each variable of interest, give sources of data 
and details of methods of assessment 
(measurement). Describe comparability of 
assessment methods if there is more than one group 
18-20 37-38 
Bias 9 Describe any efforts to address potential sources of 
bias 
  
Study size 10 Explain how the study size was arrived at 21 39 
Quantitative 
variables 
11 Explain how quantitative variables were handled in 
the analyses. If applicable, describe which groupings 
were chosen and why 
21  
Statistical methods 12 (a) Describe all statistical methods, including those 
used to control for confounding 
21 39 
(b) Describe any methods used to examine 
subgroups and interactions 
  
(c) Explain how missing data were addressed   
(d) Cohort study—If applicable, explain how loss to 
follow-up was addressed 
Case-control study—If applicable, explain how 
matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe 
analytical methods taking account of sampling 
strategy 
  
(e) Describe any sensitivity analyses   
Continued on next page  
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Results                                                                                                  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included in 
the study, completing follow-up, and analysed 
21 39 
(b) Give reasons for non-participation at each stage   
(c) Consider use of a flow diagram   
Descriptive 
data 
14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
21 39 
(b) Indicate number of participants with missing data for each variable of 
interest 
  
(c) Cohort study—Summarise follow-up time (eg, average and total amount)   
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures 
over time 
  
Case-control study—Report numbers in each exposure category, or 
summary measures of exposure 
  
Cross-sectional study—Report numbers of outcome events or summary 
measures 
  
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
  
(b) Report category boundaries when continuous variables were 
categorized 
  
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
  
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
  
Discussion  
Key results 18 Summarise key results with reference to study objectives 21-
25 
43-
45 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
33 45 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
30 43 
Generalisability 21 Discuss the generalisability (external validity) of the study results 34 45 
Other information  
Stellenbosch University https://scholar.sun.ac.za
Funding 22 Give the source of funding and the role of the funders for the present study 
and, if applicable, for the original study on which the present article is 
based 
NA NA 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and 
unexposed groups in cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological 
background and published examples of transparent reporting. The STROBE checklist is best used in conjunction 
with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of 
Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the 
STROBE Initiative is available at www.strobe-statement.org. 
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Appendix G: Turn It In Report 
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18%
SIMILARITY INDEX
12%
INTERNET SOURCES
15%
PUBLICATIONS
%
STUDENT PAPERS
1 1%
2 1%
3 1%
4 1%
5 <1%
6 <1%
MSc DM
ORIGINALITY REPORT
PRIMARY SOURCES
www.jove.com
Internet  Source
pubmed.cn
Internet  Source
Vanessa K. Noonan. "Measuring fatigue in
persons with multiple sclerosis: creating a
crosswalk between the Modified Fatigue Impact
Scale and the PROMIS Fatigue Short Form",
Quality of Life Research, 11/03/2011
Publicat ion
journals.sagepub.com
Internet  Source
Estelle Herbert, Penelope Engel-Hills,
Coenraad Hattingh, Jean-Paul Fouche et al.
"Fractional anisotropy of white matter, disability
and blood iron parameters in multiple
sclerosis", Metabolic Brain Disease, 2018
Publicat ion
Marrie, Ruth Ann, and Heather Hanwell.
"General Health Issues in Multiple Sclerosis :
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